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CHAPTER ONE
REVIEW OF LITERATURE
Hepatocellular Carcinoma-Introduction
Hepatocellular carcinoma (HCC) is a hepatobiliary malignancy that accounts for 90% of
all primary liver cancers worldwide (Jacques et al., 2015). Liver cancer is the sixth most
common cancer and fourth most common cause of cancer death worldwide (Villanueva, 2019).
The World Health Organization projected that more than 1 million patients will die from liver
cancer in 2030 (Mathers & Loncar, 2006). New case occurs frequently in developing countries,
but the incidence is rapidly on the rise in economically developed countries, especially in the US.
Most strikingly, in the US, liver cancer has exceeded all other cancers in terms of total increase
in mortality, with a near doubling in mortality rate over the past 20 years (Jacques et al., 2015).
Demographically, there is a significantly higher incidence of HCC in males, that is males are
four times more likely to get the disease than females (Uemura et al., 2016). Rate of occurrence
is also higher in African Americans, Hispanics, Asians, Pacific Islanders, and Native Americans
(Uemura et al., 2016). The prognosis for patients with HCC is very poor, with a 5-year survival
of 18%, making it the second deadliest cancer (behind pancreatic carcinoma) (Villanueva, 2019).
Because majority of HCC patients are diagnosed at intermediate or advanced stage, the 5-year
survival of these patient population is virtually 0% (Friedman, 2020; Uemura et al., 2016).
Clinical Etiology of HCC
Pathogenesis of HCC is complex and multifactorial. Most accepted theory suggests that
cell injury in the liver, persistent hepatic inflammation, abnormal liver regeneration and fibrosis
1
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will ultimately lead to the development of HCC (Uemura et al., 2016). Patients with chronic viral
hepatitis are at high risk for HCC. Hepatitis C (HCV) is responsible for about 40% of HCCs in
the US (Friedman, 2020; Uemura et al., 2016). Hepatitis B (HBV) is another important cause,
and it’s primarily associated with incidence in Asia and sub-Saharan Africa (Friedman, 2020;
Uemura et al., 2016). Alcohol and Cirrhosis are major risk factors for HCC. Cirrhosis is
associated with 85% of HCC cases and remains to be the main risk factor, although HCC
develops in a health liver in less than 10% of the cases (Forner, Llovet, & Bruix, 2012;
Friedman, 2020). Alcoholic cirrhosis causes about 15% of HCC and cholangiocarcinoma in the
US (Uemura et al., 2016). Furthermore, alcohol significantly increases the chance of developing
HCC in patients with liver diseases such as primary biliary cirrhosis, hemochromatosis, Wilson
disease, alpha-1 antitrypsin deficiency and glycogen storage disease (Uemura et al., 2016). Due
to worldwide efforts of HBV vaccination and development of direct-anti-HCV agents, the
pathogenic landscape of HCC will most likely be changed (Villanueva, 2019). And together with
the increase in nonalcoholic fatty liver disease (NAFLD) associated with metabolic syndrome
and obesity, NAFLD will soon become the leading cause of HCC in the US (Younossi et al.,
2019).
Molecular Pathogenesis of HCC
The molecular pathogenesis of HCC is complex and poorly characterized. Genetic
aberrations are frequently detected in HCC, including mutations and chromosomal abnormalities.
Employment of Next-generation sequencing has helped to identify genes commonly mutated in
HCC (Guichard et al., 2012). Similar to other cancers, every HCC disease is a unique mix of
somatic gene perturbations of both passenger (non-cancer promoting) and driver (cancerpromoting) genes (Stratton, Campbell, & Futreal, 2009). Although much of the HCC molecular
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pathology remains to be elucidated, known mutations in driver genes often belong to these
following pathways that are instrumental to hepatocarcinogenesis: 1. cell cycle regulation, 2.
Wnt/β-catenin, 3. JAK/STAT3, 4. PI3K/AKT/MTOR, 5. histone methyltransferases, 6.
chromatin remodeling, 7. oxidative stress and 8. Ras/RAF/MAPK (Fujimoto et al., 2012;
Guichard et al., 2012; Totoki et al., 2014).
TERT
The conundrum of DNA synthesis and replication that results in the continuous
shortening of chromosomes following cell division was described by Alexey Olovnikov in 1971
(Olovnikov, 1971). In the DNA replication of the lagging strand, RNA primers are necessary for
DNA synthesis because of the unidirectional limitation of the DNA polymerases. These RNADNA hybrid strands, named Okazaki fragments, form the bases for DNA synthesis in the lagging
strand. However, problem arises at the end of the replication, where DNA polymerase cannot
replace the 5′ RNA primer that is removed, and therefore DNA is lost at the ends of the
chromosomes (Blackburn, 2001). Research team led by Elizabeth Blackburn, solved the end
replication problem through the discovery of telomeres and telomerases (Greider & Blackburn,
1985, 1989). Telomeres are DNA-protein hybrid complexes at the end of chromosomes that
prevent DNA loss during replication (Blackburn, 2001).
Telomerase is an enzyme complex that synthesizes telomeres, and is highly active during
embryo development and organ regeneration (Gilson & Géli, 2007). Its main components are
telomerase reverse transcriptase (TERT), telomerase RNA component (TERC) and dyskerin.
TERT expression is the limiting factor for the activity of telomerase and is highly expressed
during embryogenesis including fetal hepatocytes (Günes & Rudolph, 2013). Conversely, TERT
expression is suppressed in the adult body, with the exception of some stem cells which allows
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the self-renewal of old or damaged tissues (Günes & Rudolph, 2013). However, no telomerase
activity is present in mature hepatocytes and cholangiocytes in the adult liver (Calado & Young,
2009).
Telomerase activity plays a dynamic and important role in hepatocarcinogenesis. Most
common mutations of HCC occur in the TERT promoter sequence, which accounts for about
60% of cases (Schulze, Nault, & Villanueva, 2016). Current theory suggests that excess alcohol
consumption, hepatitis infection and metabolic syndromes, induce inflammation, oxidative stress
and cell death that lead to progressive shortening of telomere due to compensatory tissue
regeneration (Nault, Ningarhari, Rebouissou, & Zucman-Rossi, 2019). However, when the
telomeres reach to critical length, senescence occurs with DNA damage and apoptosis. The final
phase is the transition to HCC characterized by the escape from senescence, with re-expression
of TERT that sustains rapid tumor growth and progression (Nault et al., 2019).
Because telomerase is highly activated in many cancer cells and not in normal adult cells,
it has long considered as a promising therapeutic target for HCC. Many strategies have been
developed to target telomerase activity, such as directly targeting telomerase complex activity
and telomerase-telomere interactions using molecular inhibitors, and indirect targeting of
telomerase using TERT based vaccines (Nault et al., 2019). However, none of them is currently
validated for use in HCC because of lack of antitumor activity in humans (Harley, 2008).
WNT/β-Catenin
Second most prevalent mutations involve the Wingless and Int-1 (WNT) signaling
pathway which include β-catenin (CTNNB1) and AXIN1 that account for 30% and 10% of the
cases respectively (Villanueva, 2019). Consequently, Wnt/β-catenin pathway is frequently
activated in HCC (up to 50% of cases) (Khalaf et al., 2018). CTNNB1 is a gene that encodes β-
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catenin, a key player in WNT signaling that effects tissue patterning, cell growth, selfrenewal/differentiation and angiogenesis (MacDonald, Tamai, & He, 2009). There are two
known types of WNT signaling: 1. canonical (β-catenin dependent) and 2. non-canonical (βcatenin independent) (MacDonald et al., 2009; Zhan, Rindtorff, & Boutros, 2017). In the βcatenin dependent canonical pathway, in the absence of WNT ligand, β-catenin forms the
destruction complex with adenomatous polyposis coli (APC), Axin, Glycogen synthase kinase 3
beta (GSK3β) and casein kinase (CK1α). In this complex, β-catenin is phosphorylated by
GSK3β, recognized by E3 ubiquitin ligase β-Trcp, and finally is targeted for proteosomal
degradation. Without nuclear β-catenin, T-cell factor and transducing-like enhancer protein
(TCF/TLE) repressive complex recruits specific histone deacetylase (HDACs) to suppress Wnt
target genes. Conversely, in the presence of WNT ligand, frizzled (Fzd) and lipoprotein receptorrelated protein (LRP) form a complex that leads to the recruitment of dishevelled (Dvl) proteins
and the disassembling of the destruction complex. This results in the nuclear translocation of βcatenin, where it forms an active complex with lymphoid enhancer factor (LCF) and TCF to
activate Wnt-responsive genes.
Although Wnt signaling is aberrantly activated in many cancer including HCC, there is
no effective therapy currently approved for clinical use (Khalaf et al., 2018; Vilchez, Turcios,
Marti, & Gedaly, 2016). This is likely due to the incomplete understanding of β-catenin’s role in
human hepatocarcinogenesis as current animal models do not faithfully capture the disease in
humans (Zhan et al., 2017). For example, there are many contradicting reports of the roles of
CTNNB1 mutations in the progression of HCC (Khalaf et al., 2018; Suzuki, Yano, Nakashima,
Nakashima, & Kojiro, 2002). Advanced HCC can be stratified to proliferation and nonproliferation class (Zucman-Rossi, Villanueva, Nault, & Llovet, 2015). β-catenin mutation is
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associated with non-proliferation class which is characterized by low tumor grade, lower
frequency of vascular invasion, lower serum α-fetoprotein level (prognostic marker of HCC),
highly differentiated cells similar to normal hepatocytes and better clinical outcomes (Khalaf et
al., 2018; Villanueva, 2019). These results suggest that CTNNB1 mutations is possibly an early
event and requires other oncogenic drivers for the initiation and progression of HCC (Khalaf et
al., 2018; Z. Wang et al., 2015).
TP53
The p53 transcription factor is a universal cell stress sensor that is activated by stress
stimuli such as DNA damage, redox pressure, oncogene activation (Bykov, Eriksson, Bianchi, &
Wiman, 2018). Activation of p53 drives cell-cycle arrest, senescence, apoptosis, and DNA
repair, which ultimately protect the body from propagating and deleterious mutations, and thus,
p53 has come to known as “the Guardian of the Genome” (Bykov et al., 2018). P53 is primarily
regulated by the p53 target E3 ubiquitin-protein ligase MDM2 (Kastenhuber & Lowe, 2017).
Under normal condition, p53 protein level is suppressed by MDM2 via feedback regulation,
which binds to and targets p53 for proteasome-mediated degradation. Under cellular stress,
MDM2 binding to p53 is disrupted by stress induced kinases such as ataxia telangiectasia
mutated (ATM) and Rad3-related protein (ATR) via phosphorylation, leading to p53
accumulation and activation. Furthermore, critical oncogenes such as c-Myc promotes the
activation of p53 through the p19ARF/MDM2 pathway (Eischen, Weber, Roussel, Sherr, &
Cleveland, 1999).
TP53 is mutated in over 30% of HCC cases. Majority of the mutations are loss of
function missense mutations resulting in the inactivation of p53 protein (Bykov et al., 2018).
Protective mechanism of p53-mediated apoptosis primarily depends on the pro-apoptotic
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members of the Bcl-2 family such as Bax and Bak, which have very low expression in TP53
mutated HCC (Pietsch, Sykes, McMahon, & Murphy, 2008). Newer studies showed that p53 can
regulate cancer metabolism and suppress tumor progression through ferroptosis (Jiang et al.,
2015). Moreover, p53 can activate AMPK and simultaneously suppress AKT/mTORC1
signaling through multiple mechanisms (Berkers, Maddocks, Cheung, Mor, & Vousden, 2013).
Taken together, p53 acts as a major defender against hepatocarcinogenesis. Nevertheless,
therapeutic targeting of mutated TP53 poses an immense pharmacological challenge because of
non-trivial task of restoring inactivated tumor suppressors (Bykov et al., 2018). Since the initial
discovery of p53 (DeLeo et al., 1979) and a plethora of evidences supporting its tumor
suppressive role, no therapy has been approved for use in human despite heavy research (Bykov
et al., 2018). On top of this, there are still many things we don’t know about the function of p53.
For example, in depth structure and function studies showed that selected mutations can produce
partial-loss or gain of oncogenic function demonstrating that not all p53 mutants are created
equal (Aschauer & Muller, 2016). P53 mutants are mostly classified by their effect on DNA
binding and folding; however, it’s currently impossible to predict precisely how a particular
mutation impacts function (Kastenhuber & Lowe, 2017).
STAT3
Hyperactivated STAT3 signaling has been observed in greater than 70% of human
malignancies and correlates with poor patient outcomes (Frank, 2007; Johnson, O'Keefe, &
Grandis, 2018). In the preneoplastic or tumor cells, STAT3 signaling drives the proliferation,
survival, invasiveness, and metastasis (Johnson et al., 2018; Yu, Lee, Herrmann, Buettner, &
Jove, 2014). Furthermore, it is well established that high STAT3 signaling is often observed in
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the tumor microenvironment, promoting angiogenesis, chronic oncogenic low-grade
inflammation while suppressing host antitumor response (Huynh, Chand, Gough, & Ernst, 2019).
STAT3 is a member of the seven-mammalian signal transducer and activator of
transcription (STAT) protein family that regulates many biological functions including cell
growth, differentiation, inflammation, and survival (Huynh et al., 2019; Yu et al., 2014). STAT3
signaling is also essential for self-renewal and survival of embryonic stem cells, as it’s the only
STAT protein can induces embryonic lethality after deletion (Takeda et al., 1997). While STAT3
was first identified as a transcriptional enhancer of innate inflammatory genes that is activated by
interleukin 6 (IL-6), more recent findings have demonstrated important non-transcriptional and
non-cytokine driven functions of STAT3 in oncogenesis (Yu et al., 2014). The STAT3 gene is
located on chromosome 17q21 and encodes an 89-kDa protein. There exists an alternative
splicing transcript of the full-length STAT3 (STAT3α) that encodes an 80-kDa protein known as
STAT3β. Additionally, a 72-kDa STAT3γ and a 64-kDa STAT3δ have also been discovered;
however, they exist much less frequently and correlate to early embryonic development and the
pathogenesis of disease in adults (Hevehan, Miller, & Papoutsakis, 2002; Xia et al., 2001). The
functional domains between STAT family members are highly conserved. Like most STAT
family proteins, STAT3 has 1. an amino-terminal coiled-coil domain starting at residue 130,
which enables protein-protein interactions; 2. a core DNA-binding domain from residues 320 to
490; 3. a linker region from residues 490 to 580 that influences DNA-binding stability, 4. a Src
homology 2 (SH2) domain from residues 580 to 680, 5. a crucial regulatory tyrosine residue at
705 and finally a carboxyl transactivation domain that consists of another regulatory serine site at
727, which is absent STAT3β. Phosphorylation at Y705 results in the homo- or heterodimerization of two STAT proteins by mutual phosphotyrosine interactions between the SH2
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domains of the monomers. STAT3 dimerization causes conformational change in the STAT3
proteins to promote specific DNA binding at the enhancer region of targeted genes (Bromberg et
al., 1999). In the canonical STAT3 signaling, cytokine or growth factor activates the native
receptors and shifts their conformation to allow the docking and activation of Janus kinases
(JAK) (Stark, Kerr, Williams, Silverman, & Schreiber, 1998). The activated JAKs then
phosphorylate the cytokine/growth factor receptor and generates a Src homology 2 (SH2)
domain for the recruitment of STAT3. Once brought to close proximity with JAK, STAT3 is
phosphorylated by JAK at the tyrosine 705 residue, which leads to STAT3 dimerization and
translocation to the nucleus where it enhances the transcription of target genes (Darnell, Kerr, &
Stark, 1994; Leonard & O'Shea, 1998; Stark et al., 1998).
Non-canonical STAT3 functions: It’s important to note that there’s a plethora of
cytoplasmic or non-transcriptional function of STAT3. We are going to highlight two in this
section: 1. non-transcriptional regulation of metabolism, and 2. autophagy, as they are intimately
connected to STAT3 driven oncogenesis. Recent interesting findings showed that STAT3 DNAbinding domain mutant can enhance the activity of the electron transport chain (ETC) in the
mitochondria, and promotes tumor growth that is independent from the transcriptional activity of
STAT3 (Wegrzyn et al., 2009; Zhang et al., 2013). Mechanistically, a portion of activated
STAT3 enters the mitochondria and directly interacts with complex I proteins and enhances ETC
activity by blocking the opening of the mitochondrial permeability transition pore (mPTP)
(Boengler, Hilfiker-Kleiner, Heusch, & Schulz, 2010). The role of transcriptional regulation of
STAT3 on autophagy is well established, that is, nuclear STAT3 promotes the expression of antiautophagic genes such as BCL2, MCL1 and PIKR1 (Feng et al., 2014; Tai et al., 2013).
Nevertheless, STAT can also regulate autophagy independent of its nuclear function. For
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instance, a recent study showed that cytoplasmic STAT3 can suppress autophagy by binding to
stress response protein, PKR and inhibiting its function (Shen et al., 2012). Structural analysis of
STAT3 and PKR interactions suggests that the SH2 domain of the STAT3 conformational fold
acts as a competitive inhibitor of PKR for the its substrate eIF2α (Shen et al., 2012). Since PKR
mediated phosphorylation of eIFα is critical for autophagosome formation, STAT3 has an
important non-transcriptional function at suppressing autophagy and promoting tumorigenesis.
Role of STAT3 signaling in HCC: Hyperactive STAT3 signaling was observed in over
60% of human HCCs and positively correlating with tumor aggressiveness and poor patient
outcomes (Calvisi et al., 2006; He et al., 2010). Furthermore, persistent STAT3 activation
promotes tumor progression from viral hepatitis to HCC (Nakagawa et al., 2009; Wong et al.,
2009). Mechanistically, STAT3 signaling is critical for promoting the malignant transformation
of preneoplastic cells in the development of HCC in vivo, and constitutively active STAT3
enhances the expression of multiple anti-apoptotic (such as, Bcl-2, Bcl-xl, and Mcl-1) and
mitogenic (c-myc, cyclin D1, Rb2, and CDK4) proteins in HCC cells (Radaeva, Sun, Pan, Hong,
& Gao, 2004). Most convincingly, conditional deletion of STAT3 in hepatocytes prevented
diethylnitrosamine (DEN)-induced HCC in mice (He et al., 2010). Constitutively activated
STAT3 is detected in tumor-initiating cells from HCC, and nuclear STAT3 was shown to
directly promote CD133 (an important factor in the maintenance of self-renewal in HCC cells)
expression (Ghoshal, Fuchs, & Tanabe, 2016). Similarly, a more recent study also showed that
STAT3 maintains tumor-initiating cells and consequently enhances tumor recurrence and
chemoresistance via STAT3/NANOG/CD24 axis (Terence Kin W. Lee et al., 2011).
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AKT
AKT, also known as protein kinase B (PKB), was discovered more three decades ago
(Staal, 1987) and has been extensively investigated in all fields of biology and medicine. Our
current knowledge of AKT is immense. This includes the discovery of multiple upstream
regulatory and key downstream signaling effectors such as glycogen synthase kinase 3 (GSK3),
forkhead box O (FoxO) and mTORC1 (Hoxhaj & Manning, 2020). AKT signaling is complex
and dynamically regulated by multiple branching and looping signaling network that is present in
virtually all of human tissues (Manning & Toker, 2017). In general, AKT acts mainly as a
oncodriver in almost all cancers because of its role in promoting cell survival, proliferation,
angiogenesis and more (Hoxhaj & Manning, 2020). However, therapeutic targeting of AKT is
extremely challenging due to structural similarity between protein kinases, especially in the AGC
kinase family (Nitulescu et al., 2016; Q. Wang, Chen, & Hay, 2017). The existence of three AKT
isoforms with unique functions and variability in tissue expression further complicates the
problem of designing a drug that selectively targets AKT and specific isoforms (Nitulescu et al.,
2016). Nevertheless, AKT has always been in the focus of many cancer research, and acts as a
major signal hub for many growth factors, cytokines or metabolites driven oncogenesis (Hoxhaj
& Manning, 2020).
AKT protein comprises of three domains: 1. an amino terminal (N-terminal) pleckstrin
homology (PH) domain, 2. a kinase domain, and 3. a carboxyl-terminal (C-terminal) regulatory
domain (G. Song, Ouyang, & Bao, 2005). The N-terminal pleckstrin homology (PH) domain
interacts with membrane lipid anchors such as phosphatidylinositol (3,4,5)-trisphosphate (PIP3)
and phosphatidylinositol 4,5-bisphosphate (PIP2) (G. Song et al., 2005). The kinase domain is
highly conserved among AGC protein kinases and contains a regulatory threonine residue,
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Thr308, within its activation loop. Additionally, another regulatory serine residue, Ser473, is
found on the C-terminal regulatory domain. Both phosphorylation events are essential for the full
activation of AKT signaling (G. Song et al., 2005). While there are many facets of AKT
signaling, in this section, we’ll mainly focus on the canonical growth factor driven PI3K/AKT
pathway as it is critical in many oncogenic processes. In the PI3K/AKT pathway, growth factor
ligands activate receptor tyrosine kinases (RTKs) or G-protein coupled receptors (GPCR), and
phosphoinositide 3-kinase (PI3K) is activated upon recruitment to the SH2 domains with the
regulatory phospho-tyrosine residues on activated receptors. Activation of PI3K at the plasma
membrane promotes the phosphorylation of PIP2 to the second messenger, PIP3. PIP3 clustering
at the plasma membrane generates docking sites to recruit AKT and 3-phosphoinositide
dependent protein kinase-1 (PDK1) which contains specific N-terminal PH domain that anchors
to this lipid. Consequently, binding to PIP3 brings PDK1 to close proximity of AKT, induces a
conformational change in AKT and PDK1, and promotes the phosphorylation of AKT at the
T308 of the activation loop by PDK1, which is essential for AKT activity (Manning & Toker,
2017; G. Song et al., 2005). Activated AKT phosphorylates a diverse panel of downstream
substrates including mTORC1, GSK3, FOXO, and c-MYC (Manning & Toker, 2017; G. Song et
al., 2005).
Role of AKT signaling in HCC: High AKT/mTOR signaling is frequently observed and
associates with aggressive tumor and poor clinical outcome in human (Calvisi et al., 2011;
Villanueva et al., 2008; Q. Zhou, Lui, & Yeo, 2011). Specifically, high AKT activation alone is
found to be as high as 31.2% in HCC patients (Villanueva et al., 2008). In HCC, hyperactivation
of AKT pathway is due to multiple molecular mechanisms, including constitutively active
mutations of PI3K p110 (PIK3CA), loss of negative regulator, phosphatase and tensin homolog
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(PTEN) or persistent activation of RTKs (Nakamoto, 2017; Yao et al., 1999; Q. Zhou et al.,
2011). Furthermore, inhibition of AKT suppresses HCC growth in vitro and xenograft models
(Villanueva et al., 2008), and either deletion of PTEN or overexpression of
myristoylated/constitutively-activated AKT leads to HCC development in the mouse (Calvisi et
al., 2011; Horie et al., 2004; Hu et al., 2016). Mechanistically, as mentioned previously, AKT
signaling promotes cell survival and enhances tumor metabolism in HCC by activating TORC1,
GSK3, FOXO, and c-MYC (Hoxhaj & Manning, 2020; Miao Lu et al., 2019; Mancinelli et al.,
2017; Xu et al., 2019).
Other HCC Oncogenes and Future Directions
There are other mutations in HCC such as ARID1A, ARID2, CCND1/FGF19, and
VEGFA. ARID1A is a SWI/SNF chromatin remodeling gene that is mutated in ~10% of HCC
patients (Villanueva, 2019). Because the majority of its mutations are loss of function, ARID1A
is generally accepted as a tumor suppressor. However, recent report shows that ARID1A
function is context dependent; that is, ARID1A expression is critical for the ROS dependent
tumor initiation, while loss of function in later stage promotes tumor progression by promoting
migration and invasion (Sun et al., 2017). Although DNA amplification in 6p21 and 11q13
containing cyclin-D1 (CCND1) /fibroblast growth factor 19 (FGF19) and Vascular endothelial
growth factor A (VEGFA) respectively could possibly be targeted with molecular therapy;
nevertheless, their prevalence in HCC is low (5-10%) (Villanueva, 2019).
In summary, our lack of understanding in the molecular pathogenesis of HCC has limited
the development of effective targeted therapies. Among the ones we identified, few of these
mutations can currently be targeted and translated into effective human therapies (Zehir et al.,
2017). Perhaps, with new advancements in the heterobifunctional proteolysis targeting chimera

14
(PROTAC), we can finally target the many crucial oncodrivers of HCC that lack the traditional
enzymatic pocket such as STAT3 and p53 mutants (Bai et al., 2019).
Current Therapies for HCC
The only curative treatments for HCC are surgical resection or liver transplantation. Both
of these options are limited by early detection or sparse donors respectively. Moreover, HCC
often results from chronic liver disease such as cirrhosis, which greatly hinders the success of
surgical intervention, because these treatments depend heavily on the preserved liver function of
patients (El–Serag & Rudolph, 2007). To further complicate the matter, greater than 80% of
patients with HCC have advanced disease at the time of diagnosis, and therefore, are no longer
candidates for transplantation, surgical resection or liver directed therapies (Uemura et al., 2016).
Historically, no effective systemic treatment was available for advanced HCC until 2008, when
the FDA approved the VEGFR inhibitor sorafenib as a first line treatment. Sorafenib provides
limited clinical benefit, increasing overall survival (OS) by 2.8 months compared to placebo and
achieving an overall response rate of less than 2% (J. M. Llovet et al., 2008). Despite these
unimpressive results, for nearly a decade, it was the only approved first-line therapy for
advanced HCC, while numerous other molecular therapies failed to show any superiority as firstor second-line treatments (J. M. Llovet, Villanueva, Lachenmayer, & Finn, 2015). Nevertheless,
in the recent years, additional molecular agents such as the first-line treatment lenvatinib, and the
second-line treatments regorafenib, cabozantinib and checkpoint inhibitors nivolumab and
pembrolizumab have been approved by the FDA. However, all are marked by low response rates
and limited overall survival benefit. Lenvatinib showed non-inferiority to sorafenib; regorafenib
and cabozantinib showed 2.8 and 2.2 months increase in OS compared to placebo respectively;
nivolumab showed an overall response rate (ORR) of 14.3% in a phase II trial; and,
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pembrolizumab failed to meet the pre-specified study endpoint compared to placebo in a
confirmatory phase III trial (Abou-Alfa et al., 2018; Bruix et al., 2017; El-Khoueiry et al., 2017;
Finn et al., 2019; Kudo et al., 2018).
A major challenge in drug development is that HCC has the fewest somatic mutations
among solid tumors that can be targeted pharmacologically (Villanueva, 2019). The majority of
approved therapies for advanced HCC primarily targets VEGFR, which targets the tumor
vasculature but not the crucial oncodrivers directly. Available treatments could possibly benefit
patients with amplification of the VEGFA genomic locus, but the prevalence of this copy
number aberration is low (5-10%) (Horwitz et al., 2014; Josep M. Llovet, 2014). Another major
challenge is to correctly identify crucial oncodrivers of HCC. This is particularly difficult
because HCC is highly heterogenic and its disease development involves the complex crosstalk
between tumor and non-tumor cells within its ecosystem (J. M. Llovet et al., 2015; Villanueva,
2019). For example, MET has been proposed as one of the critical oncodrivers of HCC
(Giordano & Columbano, 2014). However, a potent MET inhibitor, tivantinib, failed to provide
any benefit as second therapy even in patients with MET overexpression (Rimassa et al., 2018),
suggesting that a deeper understanding of the role of MET signaling in HCC is required for its
proper utilization as a therapeutic target. Altogether, given the poor understanding of the
pathogenesis of HCC and the lack of effective treatment options for patients with advanced
disease, there is an urgent need to identify new druggable oncodrivers of HCC.
Ephrin Type A Receptor 2
EphA2 receptor tyrosine kinase and their ligands, ephrins, have been shown to be
clinically and mechanistically important in the development of many malignancies (Genander &
Frisén, 2010; Lackmann & Boyd, 2008a; Pasquale, 2010; Jill Wykosky & Debinski, 2008).
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However, their expression pattern and roles in cancer cells and the tumor microenvironment are
perplexing, and dynamic, suggesting that simple dichotomous classification of EphA2 and its
ligands is insufficient at defining their role in cancer (Jill Wykosky & Debinski, 2008).
Furthermore, EphA2 exhibits bidirectional signaling, which adds another layer of complexity in
elucidating its mechanism of action (Kania & Klein, 2016; Pasquale, 2010). Thus, integrating indepth supermolecular chemistry with functional cancer cell biology studies may finally pave the
way to understanding the role of EphA2 in cancer. Directly connecting series of supermolecular
interactions with biological functions has been challenging. Nevertheless, recent studies of
EphA2 and its ligands have provided new insights and rekindled promises in their therapeutic
potential in cancer.
The homeostatic communication between EphA2 receptor and its ligands (ephrinA) is
crucial for maintaining normal physiology, and conversely, its disruption could lead to a
widespread of disease and pathology (Kania & Klein, 2016; Pasquale, 2008). For instance,
EphA2 signaling is known to be essential for tissue patterning and regeneration, synaptic
remodeling, vascular and bone remodeling (Genander & Frisén, 2010; Poliakov, Cotrina, &
Wilkinson, 2004) and dysregulation of EphA2 signaling has been implicated in a plethora of
human diseases including cancer, inflammatory and neurological disorders (Boyd et al., 2013;
Kania & Klein, 2016; Pasquale, 2010).
The connection between EphA2 and cancer was first identified more than 30 years ago,
when it was found to be highly expressed in human carcinogenic cell line (Hirai, Maru,
Hagiwara, Nishida, & Takaku, 1987). Several years later, EphA2’s first ephrin ligand, ephrin-A1
(EFNA1), was also identified from multiple cancer cell lines (Bartley et al., 1994). Not just
EphA2, other Eph family proteins have been shown to be connected to cancer, such as EphB2
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which is highly expressed in glioblastoma and plays a critical role in tumor progression (Nakada,
Niska, Tran, McDonough, & Berens, 2005); and also EphB4 which has been shown to promote
tumor invasion in melanoma (N.-Y. Yang, Pasquale, Owen, & Ethell, 2006).
This section briefly discusses our current knowledge of EphA2, highlighting its clinical
importance in cancer, and the origin of its puzzling function in multiple malignancies. We begin
by reviewing what is known about EphA2 signaling at the cellular level. Then we’ll dive into
their detailed receptor chemistry, teasing out their dynamic supermolecular interactions and how,
together with other non-canonical signaling mechanism, may lead us to eventually resolve this
paradox. Finally, we’ll discuss the clinical context of EphA2 in multiple human malignancies.
EphA2 and the Eph Receptor Family
Ephrin type A receptor 2 (EphA2) belongs to the largest family of RTKs collectively
known as Eph receptors (Boyd, Bartlett, & Lackmann, 2013; Pasquale, 2010). The current
Ephrin receptor family consists of 10 EphA (EphA1-10) and 6 EphB (EphB1-6) and is classified
mainly by the sequence homology of the extracellular domain, which determines their ligand
affinity. In general, EphAs binds to ephrin-As, while EphBs binds to ephrin-Bs, with the
exception of EphA4 and EphB2, which can bind to ephrin-Bs and ephrin-A5 respectively (J.-P.
Himanen et al., 2004; Pasquale, 2008; Jill Wykosky & Debinski, 2008). They were first
discovered in 1987 and found to be highly expressed in an erythropoietin producing HCC cell
line (Hirai et al., 1987). Human EPHA2 gene is located on chromosome 1p36 and encodes a 130
kDa transmembrane glycoprotein composed of 976 amino acid residues (Lindberg & Hunter,
1990). EphA2 receptor is highly homologous to the other EphA family member, nevertheless
there are critical differences in the ligand binding domain (LBD), ectodomain and
transmembrane domain (TM) regions which determine their unique functions (Sharonov, 2014;
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Chavent, 2016; Kania, 2016). Like all Eph family receptors, EphA2 is composed of 1. Nterminal extracellular LBD domain, 2. a Cys domain (consists of sushi and EGF-like motifs), 3.
fibronectin domains, 4. a TM domain, 5. an intracellular tyrosine kinase domain, 6. a
juxtamembrane region that regulates kinase activity, 7. a protein-protein interaction sterile alpha
motif (SAM) domain that’s responsible for receptor dimerization and a PDZ domain (Figure 2A)
(Kania & Klein, 2016).
A.

B.

Figure 1. Structure and Mechanism of EphA2 Signaling. A. Ephrin-A:
glycosylphosphatidylinositol (GPI), receptor binding domain (RBD); EphA2: ligand binding
domain (LBD), cysteine-rich domain (CRD), fibronectin domain (FN), tyrosine kinase (TK),
sterile alpha motif (SAM). B. Diagram depicting known modality of EphA2 signaling.
Eph receptor ligands or ephrins are also divided into A and B classes and both have a specific
extracellular receptor binding domain (RBD) (Pasquale, 2010; Jill Wykosky & Debinski, 2008).
A and B class ephrins are distinguished mainly by their membrane anchorage. Class A (EFNA)
has a glycosylphosphatidylinositol (GPI) linkage (Figure 2A), while Class B (EFNB) has a
transmembrane domain, and intracellular SH2 and PDZ domains (Kania & Klein, 2016;
Pasquale, 2010). These unique structural properties allow for “reverse” signaling that only
pertains to Eph receptors within the RTK family (Kania & Klein, 2016; Kullander & Klein,
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2002). Especially, EFNBs have been shown to exhibit canonical receptor signaling through
specific receptor mediated clustering and the subsequent recruitment of several adaptor proteins
including Src family kinases, NCK2/GRB4, and regulator of G-protein signaling 3 (RGS3).
Intriguingly, studies suggest that many of the reverse signaling pathways occurs independently
of SH2 and PDZ domain; for example, EFNB1 can directly interact with Par-6 tight junction
complex and regulate tissue permeability (H.-S. Lee, Nishanian, Mood, Bong, & Daar, 2008).
While lacking the intracellular domains, EFNAs can also exhibit reverse signaling through
multimerization with other transmembrane protein such as p75 to regulate tissue patterning and
growth (Lim et al., 2008). EphA2 binds preferentially to class A ephrins, with EFNA1 being the
most studied (Boyd et al., 2013; Pasquale, 2008, 2010). It’s also important to point out that there
are unconventional EphA2 ligands that are not within the ephrin family. For example, a recent
study showed that β-glucans can bind and activate EphA2 signaling in the oral epithelium as part
of the human innate immune defense against fungal infections (Swidergall, Solis, Lionakis, &
Filler, 2018).
Mechanism of EphA2 Cell Signaling
Eph-ephrin signaling is extremely complex as it not only exhibits multiple modes of
signaling, but is also directly stimulated by mechanical and physical force, representing the only
RTK known to be capable of bidirectional signaling (Kania & Klein, 2016; Pasquale, 2008;
Salaita et al., 2010). There are five known modes of EphA2 signaling (Figure 2B): 1. forwarding
signaling (involves signaling transduction of EFNA ligand to EphA2 receptor); 2. reverse
signaling (involves signaling transduction from EphA2 receptor to EFNA ligand); 3.
Bidirectional signaling (involves the simultaneous activation of both forward and reverse
signaling); 4. parallel signaling (involves EphA2 and EFNA on the same cell receives signals
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from EphA2 and EFNA; 5. anti-parallel signaling (involves simultaneous forward signaling
propagating in opposite directions) (Boyd et al., 2013; Kania & Klein, 2016; Pasquale, 2008,
2010). Consequently, maintaining proper EphA2 signaling is essential for many normal
physiological and developmental functions. Because of the membrane-bound nature of ephrin
ligands, EphA2 signaling allows for rapid spatiotemporal changes within a cell such as adhesion
and motility. Furthermore, EphA2 can exhibit the canonical endocrine signaling as membrane
tether EFNA1 can be cleaved by metalloprotease into a soluble monomeric form. This
monomeric EFNA1 has also been reported to activate EphA2 signaling independent of cell-cell
contact, and is crucial for neuronal development and pathogenesis of diseases (Chang, Jorgensen,
Pawson, & Hedley, 2008; Pasquale, 2008, 2010).
The Paradoxical role forward signaling: In the canonical forward signaling, EphA2 binds
to its membrane tethered ligand, EFNAs, on a different cell (trans conformation) and activates its
kinase activity, leading to the autophosphorylation of its juxtamembrane Tyr residues (Y588 and
Y594) that allows for the assembly of multimeric EphA2 signaling clusters (Binns et al., 2000,
Fang et al., 2008). In most cases EphA2 signaling clusters are essential for the activation of
ephrins-EphA2 directed cellular responses (Davis et al., 1994). These clusters can recruit adapter
proteins and secondary messengers that activate the EphA2 signaling cascade such as protooncogene tyrosine-protein kinase (Src), focal adhesion kinase (FAK), and ABL kinases, which
ultimately regulates cell adhesion and migration (Boyd et al., 2013; Pasquale, 2010).
Additionally, it can also regulate cell proliferation and survival via AKT and MAPK pathway
(Macrae et al., 2005; Hui Miao et al., 2009). However, it’s incredibly challenging to
unambiguously determine EphA2’s signaling pathway because of the complexity of its signaling
mechanism. EphA2 signaling is highly tissue dependent, that is, the same EFNA-EphA2
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interactions can result in dramatically different and even opposing outcomes (Boyd et al., 2013;
Kania & Klein, 2016). For instance, one study showed that EFNA1-EphA2 signaling promotes
axonal adhesion and neuronal spreading through activation of focal adhesion kinase (FAK)
(Carter, Nakamoto, Hirai, & Hunter, 2002), while a previous study also demonstrated that the
same forward signaling inhibits FAK via the phosphatase SHP2 and prevents neuron migration
and spreading (Hui Miao, Burnett, Kinch, Simon, & Wang, 2000). Furthermore, studies have
reported many other contradictory Eph-signaling responses such as proliferation and apoptosis
(Lackmann & Boyd, 2008b; Pasquale, 2010), tumor suppressive and promotion (Pasquale, 2010;
Jill Wykosky & Debinski, 2008), and self-renewal and differentiation (Genander & Frisén, 2010;
Lackmann & Boyd, 2008b). Cells can also secrete monomeric EFNAs and activate EphA2
forward signaling independent from cell contact (J. Wykosky et al., 2008), and this pathway
activates a different set of adaptors and responses (Salaita et al., 2010).
An in-depth Look at the Structure and Supermolecular Chemistry of Ephrin Signaling
Given perplexing paradoxical phenomenon of Ephrin signaling even at the protein level,
it’s essential to study Ephrin receptor dynamics at the molecular level to resolve this
phenomenon. An important question to ask is how does the same Eph receptor and ephrin
interaction produce dramatically different response? For example, how does it both inhibit
FAK and promote FAK in apparently the same tissue? Many studies have investigated the
molecular structures for Eph receptors, and discovered that the dynamics of supermolecular
assembly of Eph receptor and ephrin ligand complex are critical for tuning Eph receptor
signaling output (Davis et al., 1994; J. P. Himanen et al., 2010).
Ephrin signaling cluster. Upon ligand binding, Eph receptors and ligands (Eph-efn)
form heterooligomeric clusters which allow for activation of downstream signaling pathways,
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and the c-terminal ectodomain region of LBD is essential for ligand binding and function
(Lackmann et al., 1998). More detailed structural study revealed that the proper and functional
EphA2 signaling clusters at the cell surface require bivalent homotypic interactions between the
LBD and CRD domains in neighboring receptors that are facilitated by the frequency of ephrin
ligand intercalations (J. P. Himanen et al., 2010). Interestingly, heavy EphA2 clustering has been
associated with metastasis and invasion by cancer cells (Choi et al., 2009; J. P. Himanen et al.,
2010; Lackmann & Boyd, 2008a). Furthermore, overexpression of EphA2 is frequency observed
in and functionally connected to many malignancies, and at high concentrations, Eph receptors
can cluster independent of ligands, providing a mechanism for its oncogenic role (J. P. Himanen
et al., 2010; Kania & Klein, 2016; Pasquale, 2010). Nevertheless, not all Eph signaling clusters
are created equal. Many of the pioneer structural studies of Eph came from the neuronal systems
showing that the efficiency Ephrin forward signaling depends heavily on the stoichiochemistry
of the Eph heteromultimeric clusters (Lackmann et al., 1998; Liang, Patel, Janes, Murphy, &
Lucet, 2019; Stapleton, Balan, Pawson, & Sicheri, 1999). For instance, one study showed that
Ephrin forward signaling favors bivalent 2:2 binding of ligand to Ephrin receptor ratio compared
to monovalent 2:1 (Pabbisetty et al., 2007). The bivalent binding significantly decreases the
dissociation rate constant with minimal effect on the association rate constant, leading to up to
6000-fold decrease in equilibrium dissociation constants for the binding of dimeric ephrins to
Eph receptors relative to their monovalent counterparts, resulting in dramatically enhanced
Ephrin forward signaling (Pabbisetty et al., 2007). Thus, this provide an explanation that the
same Eph-efn interaction can have very different outcome depending on the stoichiometry and
post-translational modification of the Ephrin proteins.
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Structural regulation of Eph signaling. As described previously, there are many
physical and chemical cues that can perturb and organize Eph heteromeric clusters which will
lead to many diverse functions of Eph signaling. Perhaps the most influential and intriguing
finding is that EphA2 can detect physical forces of the cellular environment (Salaita et al., 2010).
This study showed that EphA2-EFNA1 binding, clustering, lateral transport on the plasma
membrane were affected by mechanical forces that alter the spatiotemporal geometry of
EphA2 receptors which consequently alter their signaling function (Salaita et al., 2010).
More importantly, many reports demonstrated that although both normal and tumor cells exhibit
EphA2 signaling; however, cancer cells condensed into very large macroscopic EphA2 signaling
clusters containing thousands of receptors (J. P. Himanen et al., 2010; Salaita et al., 2010; Jill
Wykosky & Debinski, 2008), resulting in the recruitment and activation of Src and CD44,
proteins promoting tumorigenesis and metastasis (J. P. Himanen et al., 2010; Salaita et al., 2010;
Singh et al., 2015). Furthermore, using advanced lithography techniques, nanofabricated physical
barriers were constructed to disrupt EphA2 clustering in cancer cells by limiting radial
movement of EphA2 (Lohmüller, Xu, & Groves, 2013; Salaita et al., 2010). These “spatial
mutations” consequently suppressed cancer cell invasion and self-renewal potential (Lohmüller
et al., 2013; Salaita et al., 2010). Thus, this provides another important insight to how the same
Eph-efn interaction can produce dramatically different outcome. Given the unique mechanical
environment, “every push, twist, and turn made by cells” and induced by the microenvironment
could fine-tune EphA2 signaling to properly coordinate normal cell physiology (Kania & Klein,
2016; Salaita et al., 2010). Subtle or aberrant changes in spatiotemporal organization of EphA2
signaling clusters could lead the development of many pathologies including cancer.
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The assembly of EphA2 signaling cluster depends heavily on the chemistry of its
“lipid rafts”. Lipid rafts are plasma membrane microdomains enriched in specially
functionalized cholesterol and sphingolipids that are involved in the lateral compartmentalization
of receptors and signaling molecule at the cell surface (Chavent, Seiradake, Jones, & Sansom,
2016; Munro, 2003). Studies have shown that both the transmembrane domain (TM) and the
membrane-proximal fibronectin domain 2 (FN2) interact with lipid bilayers. Specifically, ionic
interaction facilitated by specific lysine and arginine residues within FN2 of EphA2 receptor is
essential for its association with anionic lipids (Chavent et al., 2016; Sharonov et al., 2014).
Furthermore, activated EphA2 receptor has been shown to preferentially assemble to negatively
charged lipids for some of its functions (Gauthier & Robbins, 2003; Tawadros, Brown, Hart, &
Clarke, 2012), suggesting that depending on the post-translational modifications and chemical
composition of the lipid rafts, the same Eph-efn interaction could produce different signaling
output. For instance, different cell types or the same cells under different conditions have
dramatically different cell membrane chemical composition (Coskun & Simons, 2011). These
differences in lipid composition can specifically alter the organization of receptor signaling
clusters through stereoelectric effects.
Other EphA2 signaling mechanisms. Reports have also suggested that EphA2 and
EFNAs can interact on the membrane of the same cell (or cis conformation), and that this
interferes with trans EFNA-EphA2 clustering, and suppresses forward signaling mechanism
(Yin et al., 2004). This precise regulation of EFNAs expression is essential for the topographical
mapping of neuronal network as forward signaling from EphA2 promotes axon repulsion (Kao &
Kania, 2011). In addition to the catalytic functions of Ephrin receptor signaling, important
kinase-independent functions of Ephrin signaling have also been reported. Almost all Ephrin
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receptor gene has at least one isoform that does not have kinase activity (Liang et al., 2019). For
example, kinase-dead mutant EphA4 is able to rescue key functions of the wild-type receptor in
central nervous system development (Kullander et al., 2001). Moreover, proteolytic cleavage of
the LBD of EphA2 was shown to activate Src/RhoA activity and lead to increase tumor invasion
(Sugiyama et al., 2013), and an unliganded-monomeric EphA2 mutant that lacks tyrosine
phosphorylation can promote tumor invasion (Singh et al., 2015).
EphA2 in Cancer
Since EphA2 and the Eph receptor family were initially discovered in human carcinomas
over 30 years ago, a number of studies have investigated their functional roles in tumorigenesis
(Hirai et al., 1987). We now know that high EphA2 expression and signaling are frequently
detected in many cancers (including brain, breast, lung, etc.), are also associated with poor
patient outcomes, and can functionally promote tumor development in several malignancies
(Boyd et al., 2013; Pasquale, 2010; Jill Wykosky & Debinski, 2008).
EphA2 in breast cancer. EphA2 is overexpressed in many aggressive breast cancerderived cell lines, such as Hs578T, MDA-435, MDA-231 and BT549. EphA2 is preferentially
expressed and phosphorylated in human breast cancer tissue (Zelinski, Zantek, Stewart, Irizarry,
& Kinch, 2001). Stable expression of EphA2 in benign breast epithelial cell line MCF10A
resulted in aggressive mesenchymal morphology (Hochgräfe et al., 2010; Zelinski et al., 2001).
Furthermore, while the wild type MCF-10A cells did not develop tumors in mice, the EphA2tranformed cells formed tumors demonstrating that EphA2 overexpression alone was sufficient
to malignantly transform normal mammary epithelia cells (Zelinski et al., 2001). Interestingly,
overexpression of EphA2 in MCF7 cells decreased estrogen dependency, enhanced
tumorigenicity and resistance to tamoxifen therapy (Ming Lu, Miller, Gokmen-Polar, Jeng, &
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Kinch, 2003). Conversely, tamoxifen-resistant breast cancer cell line showed significantly
upregulated EphA2 expression (C. Zhou et al., 2012), and inhibition of EphA2 restored
sensitivity to tamoxifen therapy (Gokmen-Polar et al., 2009). Increased EphA2 expression
correlated to poor overall and disease-free survival in human epidermal growth factor receptor 2
(Her2) positive breast cancer patients (Youngblood et al., 2016; Zhuang et al., 2010).
Mechanistically, EphA2 is critical for promoting trastuzumab resistance (a first line therapy
against Her2+ breast cancer), and trastuzumab-resistant cell lines showed overexpression of
EphA2, and inhibition of EphA2 restored sensitivity to trastuzumab treatment in vivo (Zhuang et
al., 2010). Recent studies have also suggested that EphA2 plays an important role in the
development on triple-negative breast cancer (TNBC) (W. Song et al., 2017; Torres-Adorno et
al., 2019), a subtype of breast cancers known for its aggressiveness, lack of effective therapeutic
targets and very poor clinical outcome (Ismail-Khan & Bui, 2010). Not only that EphA2
expression is highly expressed and correlates to poor prognosis in TNBC, but also inhibition of
EphA2 function in both human and genetically engineered mouse models of TNBC suppressed
tumor development in vivo (W. Song et al., 2017). Mechanistically, inhibition of EphA2
impaired tumor cell cycle progression via suppression of the c-Myc and upregulation of the
p27/KIP1 axis (W. Song et al., 2017).
EphA2 in glioblastoma. In glioblastoma, EphA2 was shown to promote self-renewal
and invasion of tumor-propagating cells (Binda et al., 2012; H. Miao et al., 2015). Glioblastoma
Multiforme (GBM) is the deadliest primary brain tumors as patients continue to have very poor
clinical outcome despite advances in chemo-and-radiotherapies (Adamson et al., 2009; Hanif,
Muzaffar, Perveen, Malhi, & Simjee, 2017). EphA2 was found to be highly expressed in many
GBM-derived cell lines (such as A-172MG, DBTRG-05MG, U251MG and G48) compared to
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benign-glia-derived cell lines (Jill Wykosky, Gibo, Stanton, & Debinski, 2005). In human GBM
tissues, EphA2 expression is elevated comparing to normal brain tissues, and negatively
correlated to glioblastoma patient survival (Liu et al., 2006; Jill Wykosky et al., 2005).
Interestingly, in glioblastoma, EphA2 is often non-phosphorylated and correlated to decreased
expression of EphrinA1 (Hui Miao et al., 2009; Tandon, Vemula, & Mittal, 2011). More recent
studies showed that EphA2 signaling can promote invasiveness and progression of glioma by
maintaining self-renewal and propagation of glioma stem cells (GSC) (Affinito et al., 2020;
Binda et al., 2012; Genander & Frisén, 2010; H. Miao et al., 2015). EphA2 is overexpressed in
GSCs, and positively correlates with the size and tumor-propagating ability of the GSC pool
(Binda et al., 2012). Another study showed that expression of EphA2 promoted intracranial
invasion of GSC and maintained the stem cell properties of GSCs, promoting self-renewal and
tumorigenicity via AKT dependent EphA2/SOX2 axis (H. Miao et al., 2015).
EphA2 in lung cancer. EphA2 was found to be highly expressed in more than 70% of
the carcinoma tissues from non-small cell lung cancer patients (Kinch, Moore, & Harpole, 2003),
and high levels of EphA2 protein correlated to brain metastasis, cancer relapse, and poor patient
outcome, as greater level of EphA2 is observed in clinically advanced form of the disease
(Brannan et al., 2009; Kinch et al., 2003). Oncogenic EphA2 mutation has also been identified
NSCLC patients (Faoro et al., 2010; Tan et al., 2019). One clinically prevalent mutation at
G391R led to the constitutive activation of EphA2 and subsequent downstream activation of Src,
cortactin, and p130Cas, which dramatically enhanced invasion in NSCLC cells (Faoro et al.,
2010). At the same time, G391R also activated mTOR signaling and promoted survival of
NSCLC cells (Faoro et al., 2010). A more recent study showed that inhibition of EphA2
suppressed the tumor growth of Kras-mutant NSCLC in vivo by suppressing S6K1-mediated

28
activation of BAD and promoting apoptosis (Amato et al., 2014). Importantly, selective kinase
inhibitors of EphA2 demonstrated great efficacy against NSCLC in many mouse models,
supporting their therapeutic potential (Boyd et al., 2013; Tandon et al., 2011; Jill Wykosky &
Debinski, 2008).
EphA2 in HCC. Despite being first discovered as a uniquely overexpressed protein in
the erythropoietin producing human HCC cell line ETL-1 (Hirai et al., 1987), the role of EphA2
in HCC has not been well explored. Currently There is no detailed study of the role of EphA2 in
HCC; however, several clinical reports suggested that expression of EphA2 and/or its ligands
correlated to tumor progression, invasion, metastasis, and poor prognosis in patients with HCC
(Cui et al., 2010; C. F. Lee et al., 2009; P. Yang et al., 2009). Other studies have also shown that
micro RNAs impair tumorigenesis and enhance the efficacy of radiation therapy through direct
inhibition of EphA2 expression in HCC (Li et al., 2015; Xiang et al., 2019). Interestingly, a
recent study showed that EphA2 is highly activated in sorafenib-resistant HCC cells suggesting
EphA2 may also promote drug resistance to current therapy in HCC (Leung et al., 2019).
However, the role of EphA2 and its mechanism of action in HCC development remain unknown.
In this study, I discovered mechanisms underlying how EphA2 regulates tumor initiation and
progression in HCC, and explored the therapeutic potential of targeting EphA2 in HCC.

CHAPTER TWO
STATEMENT OF PURPOSE
Hepatocellular carcinoma (HCC) is a worldwide malignancy which accounts for 90% of
all primary liver cancers (Uemura et al., 2016). It is the sixth most common cancer and third
most common cause of cancer death worldwide, and represents a major global health problem.
Liver cancer has become increasingly important in the US, as American Cancer Society
estimates that there will be 42,220 new cases and 30,200 people will die from liver cancer in
2018. Most strikingly, over the past two decades liver cancer has exceeded all other cancers in
terms of total increase in mortality, with a near doubling in mortality rate over the past 20 years
(Llovet, Villanueva, Lachenmayer, & Finn, 2015). The prognosis for HCC patient is very poor
with a 5-year survival of less than 18% (Villanueva, 2019). The only curative treatments for
HCC are surgical resection or liver transplantation. Both of these options are limited by early
detection or sparse donors respectively, while more than 80% of HCC patient are diagnosed at
advanced stages of the disease when surgical intervention is no longer an option (Uemura et al.,
2016). Moreover, HCC often results from chronic liver disease such as cirrhosis, which greatly
hinders the success of surgical intervention (Friedman, 2020). Historically, no effective systemic
treatment was available for advanced HCC until 2008, when the FDA approved sorafenib as a
first line treatment. Although sorafenib provides limited clinical activity with an increase in
overall survival in HCC patients of 2.8 months and overall response rate of less than 2%
compared to placebo (Llovet et al., 2008), it has long stood as the only therapy for advanced
HCC, while numerous molecular therapies failed to provide any superiority as first or second
29
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line treatment (Llovet et al., 2015). In the recent year, targeted therapy has again rekindled hope
for patients suffering from advanced HCC, with the approval of several targeted therapy such as
the first-line treatment lenvatinib, and second-line treatments regorafenib, cabozantinib and
checkpoint inhibitors nivolumab and pembrolizumab. However, all are marked by low response
rates and limited overall survival benefit (Abou-Alfa et al., 2018; Bruix et al., 2017; El-Khoueiry
et al., 2017; Finn et al., 2019; Kudo et al., 2018). Given the lack of treatment options and
efficacy for patients with HCC, there is an urgent need to find new druggable and effective
molecular targets.
Ephrin Receptor class A-2 (EphA2) belongs to the largest family of RTKs collectively
known as Eph receptors (Wykosky & Debinski, 2008). Like all Eph family receptors, EphA2 is
composed of N-terminal extracellular ligand binding domain, intracellular tyrosine kinase
domain, juxtamembrane region that regulates kinase activity, and protein-protein interaction
sterile alpha motif (SAM) domain. EphA2 binds to 10 class-A glycosylphosphatidylinositollinked and transmembrane ephrin ligands, EFNA1 being the most studied (Kania & Klein, 2016;
Tandon, Vemula, & Mittal, 2011). Eph-ephrin signaling is extremely complex as it not only
exhibits multiple modes of signaling, but is also directly stimulated by mechanical and physical
force, representing the only family of RTKs known to be capable of bidirectional signaling
(Boyd, Bartlett, & Lackmann, 2013; Kania & Klein, 2016; Pasquale, 2010). The tethered ephrin
ligands allows for rapid short-distance communications between cells affecting cell adhesion and
motility (Kania & Klein, 2016). In addition, EphA2 can also exhibit the canonical RTK
signaling, that is, cells can secrete soluble ephrin ligands that activate EphA2 through endocrine
signaling (Wykosky & Debinski, 2008). Ephrin signaling is known to be essential for tissue
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patterning and regeneration, synaptic remodeling, vascular and bone remodeling (Genander &
Frisén, 2010; Lackmann & Boyd, 2008; Poliakov, Cotrina, & Wilkinson, 2004).
Dysregulation of EphA2 signaling is known to cause many pathologies including cancer.
EphA2 expression is upregulated in many cancers and correlates to increased malignancy and
poor clinical prognosis in breast, brain, and lung cancers (Pasquale, 2008, 2010; Tandon et al.,
2011; Wykosky & Debinski, 2008). Extensive studies have led to many ongoing clinical trials
that target EphA2 in these malignancies. However, the lack of insight to EphA2 signaling in
cancer has hindered the development of drugs that directly target the function of the receptor
(Boyd et al., 2013).
In HCC, clinical reports around the world have correlated both EphA2 and its ligands
EFNAs with tumor progression and poor patient outcome (Cui et al., 2010; Lee et al., 2009;
Yang et al., 2009). However, very little is known about the role of EphA2 in HCC. Thus, given
clinical relevance of EphA2, understanding the mechanistic role of EphA2 in HCC
provides a greater understanding of the pathogenesis of HCC, and ultimately develop
promising therapy for patients. This is especially important for HCC as it’s one of deadliest
malignancies (second only to pancreatic cancer), and most patients are diagnosed at the advanced
stage and has no effective treatment options.
A particularly important goal of this project is to elucidate the mechanism of oncogenic
EphA2 signaling, as EphA2 signaling is extremely complex and response is highly organ and
tissue dependent (Boyd et al., 2013; Lackmann & Boyd, 2008; Pasquale, 2010). Mechanisms
discovered in my study may provide powerful proof-of-concept for the treatment of other
malignancies as EphA2 is known to upregulated and correlate to poor prognosis in many
cancers. Considering the complex modality of EphA2 signaling, I employed on top-down
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approach to study EphA2 in HCC. In this study, I focused on the forward signaling modality of
EphA2, and discovered new unconventional EphA2 signaling in HCC. Most importantly, I
unraveled a novel signaling pathway of EphA2 never reported in cancer. Together, my findings
provide a promising therapeutic strategy for HCC, and established a foundation for the functional
targeting of EphA2 across many cancers.
Specific Aim 1: To determine the role of EphA2 in HCC by analyzing HCC patients’ expression
profile in correlation with clinical outcome, and genetic manipulation of EphA2 in human HCC
cell lines and mouse model of HCC.
Specific Aim 2: To determine the mechanism by which EphA2 promote hepatocarcinogenesis,
using cell-based and mouse model of HCC.
Specific Aim 3: To determine the therapeutic potential of targeting EphA2 in HCC by testing the
efficacy of potent EphA2 inhibitor ALW-II-41-27 in cell-based and mouse model of HCC.

Figure 2. The Objective and Aims of the Project. Aim 1: To determine the role of
EphA2 in HCC. Aim 2: To determine the mechanism by which EphA2 promote
hepatocarcinogenesis. Aim 3: To determine the therapeutic potential of targeting EphA2
in HCC. Parts of the diagram are adapted from (Brown, Heinrich, & Greten, 2018;
Siddiqui, Sanna, Ahmad, Sechi, & Mukhtar, 2015).

CHAPTER THREE
MATERIALS AND METHODS
Cell Lines
HCC Cell lines were acquired from American Type Culture Collection (ATCC®) or the
Japanese Cancer Research Resources Bank (JCRB). Huh7, Hep3B and PLC/PRF/5 were
maintained in Dulbecco's modified Eagle's (DMEM) high glucose medium (Thermo scientific,
Waltham, MA) supplemented with 10% fetal bovine serum (Tissue Culture Biologicals),
penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO) in a humidified atmosphere of 5% CO2
at 37°C. SNU387, SNU423, SNU449 and SNU475 were cultured in RPMI 1640 supplemented
with 10% fetal bovine serum (Tissue Culture Biologicals), 1x penicillin/streptomycin (SigmaAldrich, St. Louis, MO) at 37°C and 5% CO2.
Mouse Models
All animals received humane care according to the “Guide for the Care and Use of
Laboratory Animals” (http://oacu.od.nih.gov.archer.luhs.org/ac_cbt/guide3.htm). All animal
procedures were approved by the Institutional Animal Care and Use Committee at Loyola
University Chicago. The mice were housed in micro-isolator cages in a room illuminated from
7:00 AM to 7:00 PM (12:12-hr light-dark cycle), and allowed access to water and chow ad
libitum.
Xenograft Experiments
NSG-A2 mice were purchased from Jackson Laboratory (009617). Mice were all 8 – 10
weeks old, 1:1 males to female and evenly distributed in the experimental and control groups.For
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the EphA2 knockdown and AKT and STAT3 rescue studies, 3x106 cells were injected
into the right and/or left flank of the mice (depending on the experiment). Mice were monitored
for tumor growth by digital caliper. Growth volume was calculated as volume=length ×
width2/2. Tumor was extracted for analysis described in paper. The method for the ALW-II-4127 study was adopted from Dr. Jin Chen Lab (Vanberbilt) (Song et al., 2017) with modifications.
5x106 cells were injected into right flank of the mice. When tumor reached ≥200 mm3 at day 10,
mice were treated with 15 mg/kg of ALW-II-41-27 dissolved in 10%1-methyl-2-pyrrolidinone
and 90% polyethylene glycol 300 (Sigma) injected intraperitoneally once daily for 7 days.
Tumors were measured daily, and tumor volume was calculated as described previously.
In vivo limiting dilution experiment: EphA2 high and EphA2 low Huh7 sorted populations were
injected subcutaneously into the flanks of NSG-A2 mice at 50,000 and 500,000 cells. After 8–10
weeks mice were sacrificed, tumors were removed, fixed in 10% neutral buffered formalin
solution and paraffin embedded.
Hydrodynamic Gene Delivery and Immunocompetent Murine HCC Models
C57BL/6 mice were purchased from Jackson Laboratory (#000664) for the in vivo
CRISPR and MET/CAT HCC models. Mice were all 8 – 10 weeks old, 1:1 males to female and
evenly distributed in experimental and control groups. To knockout EphA2 in the MET/CATinduced HCC model, 72.5 µg of total plasmids was dissolved in 2 mL of 0.9% saline and
hydrodynamically injected each mice. The plasmids encode the single vector PX330-sgEphA2CRISPR CAS9 (sgEphA2) or pX330-U6-Chimeric_BB-CBh-hSpCas9 (PX330, empty vector
control), Sleeping Beauty transposase (HSB2) and transposons with oncogenes MET/CAT
(22.5µg sgEphA2 or 22.5 μg PX330 + 22.5µg pT3-EF1α-c-MET(human) + 22.5µg pT3-EF1αΔN90-β-catenin (human) + 5 µg HSB2). Mice were monitored for approximately 6-9 weeks total
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as this is the average time span for MET/CAT mice to develop end-stage HCC symptoms
including ascites and liver failure. Mice were then sacrificed, and livers were collected for
analysis.
Plasmids
The plasmids pT3-internal ribosome entry site (IRES) - green fluorescent protein (GFP),
pT3-CAT, and pT3-MET were previously generated by Gateway cloning (Shang et al., 2015).
sgEphA2-1, sgEphA2-2 and sgEphA3 target sequences were designed based on library and
protocol from Feng Zhang Lab (Cong et al., 2013a), and the final plasmids pX330-sgEphA2-1,
pX330-sgEphA2-2, pX330-sgEphA2-3 were constructed by cloning EphA2-target sequences into
pX330-U6-Chimeric_BB-CBh-hSpCas9 backbone following the protocol from Feng Zhang Lab
(Cong et al., 2013b). The plasmids were purified using the GeneJET Plasmid Maxiprep Kit
(Thermo Fisher Scientific) for hydrodynamic tail vein injection.
The following plasmids were purchased: pCMV-dR8.2 dvpr (Addgene, #8455) (Stewart
et al., 2003). pCMV-VSV-G (Addgene, #8454) (Stewart et al., 2003), pLKO.1-puro-shEphA21(Millipore Sigma, TRCN0000231647), pLKO.1-puro-shEphA2-2 (Millipore Sigma,
TRCN0000195734), pLKO.1-puro-shEphA2-5 (Millipore Sigma, TRCN0000231648), FG12
(Addgene, #14884), pMD2.G (Addgene, #12259), pLX304 (Addgene, #25890) (Yang et al.,
2011).
pLX304-STAT3/V5 was obtained from DNASU (cat. no. HsCD00443857). FG12-cmv-CAAKT and pLX304-FLAG/V5 were generously donated from Dr. Mitchell Denning (Loyola
University Chicago), and Dr. Takashi Shimamura (University of Illinois Chicago), respectively.
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Antibodies
Primary antibodies targeting the following proteins were obtained. From Cell signaling:
Phospho-EphA2 (Y588) (#12677, 1:1000), Phospho-EphA2 (S897) (#6347, 1:1000), PhosphoAKT (S473) (#4060, 1:2000), Phospho-AKT (T308) (#4056, 1:1000), AKT (#9272, 1:1000),
Phospho-STAT3 (Y705) (#9145, 1:1000), STAT3 (#9139, 1:1000), MET (#8198, 1:1000), Ki-67
(#12202), Phospho-JAK1 (Y1034/1035) (#74129, 1:1000), JAK1 (#3344, 1:1000). From Santa
Cruz: EphA2 (sc-398832, 1:1000). From Sigma-Aldrich: β-Actin (A5441, 1:1000). From
Thermo Fisher Scientific: GAPDH (MA5-15738, 1:1000). From BD Biosciences: β-Catenin
(#610153, 1:1000). From Agilent: Alpha-1-Fetoprotein (A0008). The following secondary
antibodies were obtained. From Thermo Fisher Scientific: Goat anti-Mouse IgG (H+L) CrossAdsorbed Secondary Antibody (#31432, 1:5000), Goat anti-Rabbit IgG (H+L) Cross-Adsorbed
Secondary Antibody (#31462, 1:5000), Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary
Antibody, Biotin (#31822, 1:500), Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary
Antibody, Biotin (#31802, 1:500), Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary
Antibody, Alexa Fluor 488 (A-11001, 1:500), Goat anti-Rabbit IgG (H+L) Highly CrossAdsorbed Secondary Antibody, Alexa Fluor 594 (A-11037, 1:500).
Western Blot
Cells/tissue lysate was prepared in RIPA lysis and extraction buffer (Thermo Scientific)
supplemented with proteinase (Thermo-Scientific A32953) and phosphatase (Thermo-scientific
A32957). Protein was quantified using the Pierce protein assay (Thermo-Scientific #1861426).
SDS–polyacrylamide gel electrophoresis was performed using 10% acrylamide gels, and
proteins were transferred to nitrocellulose membranes using the Trans-Blot Turbo transfer
system (Bio-Rad). Membranes were blocked in 5% milk for 1 hour and incubated overnight at
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4°C with primary antibodies with manufacture-recommended concentrations in 5% bovine serum
albumin. After several washes with TBS-T (20 mM Tris (pH 7.6), 140 mM NaCl, and 0.1%
Tween 20), blots were incubated with the appropriate HRP-conjugated secondary antibody
(Thermo-Fisher Scientific) and imaged using the iBrightCL1000 (Thermo-Fisher). Signals were
quantified using ImageJ.
Flowcytometry and Fluorescence Antibodies
Antibodies used for flow cytometry application include: Human EphA2 PE-conjugated
Antibody (R&D Systems; FAB3035P), and FITC Mouse Anti-Human EpCAM (BD Biosciences,
#347197). EphA2 and EPCAM stainings were detected using a BD LSRFortessa™ (BD
Biosciences, U.S.). Cell sorting of EphA2 expression HCC cells was done using BD
FACSAria™ III. FACS data was analyzed using FlowJo Software.
Immunohistochemistry and Immunofluorescence
Tissue Processing and Slide Preparation
Mouse liver tissues was dissected, and placed in 10% buffered formalin overnight at
room temperature and dehydrated in a series of graded alcohol. Human HCC specimens were
provided by Loyola University Medical Center Pathology Core, and human and mouse liver
tissues were paraffin-embedded by the Loyola Pathology Core. Human HCC tissue microarrays
were provided by Dr. Robert Lewis and the Mayo Clinic Hepatobiliary SPORE. Tissue blocks
were cut into 4 μm sections, dewaxed and rehydrated.
Immunohistochemistry
After heat-mediated-citrate-based antigen retrieval, slides were then washed in TBS, and
blocked using 5% goat serum for 1 h at room temperature before incubation with primary
antibodies for 1 hour at room temperature: Y588 p-EphA2 (1:100), EphA2 (1:200), s473 p-AKT

38
(1:200), p-JAK1 (1:100), p-STAT3 (1:100), AFP (1:200), Ki67 (1:200). Slides were washed in
TBST and incubated with biotin conjugated goat secondary antibody (Thermo Fisher Scientific,
depending on the type of species) for 1 hour. Next slides were incubated with VECTASTAIN®
ABC HRP reagent for 30 min at room temperature. Slides were washed in TBST followed by
detection by DAB staining for 5 min (Vector Laboratories, SK-4100) for 5 min and finally
counterstained with haematoxylin. The IHC signals were quantified visually. The staining was
scored as – (0, negative), + (1, weak signal), + + (2, moderate signal), + + + (3, strong signal) by
three independent observers including a pathologist from Loyola University Chicago, who was
masked as to patient outcome. The average score k was calculated and categorized as negative
(k=0), low (0<k<1.5), or high (k>1.5)
Immunofluorescence
Following the incubation with primary antibody and TBST wash, fluorophore-conjugated
goat secondary antibody (Thermo Fisher Scientific, depending on the species) was incubated for
1 hour. Slides were then washed in TBST followed by nuclear staining with DAPI mounting
media (Vector Laboratories, H-1200)
Lentivirus Particle Production and Transduction
All lentiviral particles were produced in HEK293 cells. The protocol was based on
Addgene's lentivirus production protocol with modifications. HEK293 packaging cells were
plated onto 10 cm dishes at 3x106 cells for overnight. Two packaging plasmids pCMV-dR8.2
dvpr (Addgene, #8455) pCMV-VSV-G (Addgene, #8454) plus pLKO-based transfer plasmids
were diluted in Opti-MEM (Gibco) with 1 mg/ml PEI at the DNA:PEI ratio of 1:4. Plasmid
mixtures were transfected into cells and the media was replaced with complete DMEM 18 hours
after transfection. Lentivirus was harvested 72 hours post transfection. Collected media was
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centrifuged at 500 × g for 10 min and supernatant was extracted and stored at -80°C. Lentivirus
transduction was performed following the Addgene PLKO.1 protocol.
Gene Knockdown
EphA2 Knockdown Experiment
Knockdown of EphA2 in HCC cell lines was performed using lentiviral mediate shRNA
expression. pLKO.1-puro-shEphA21(CCGGCCATCAAGATGCAGCAGTATACTCGAGTATACTGCTGCATCTTGATGGTTTT
TG), pLKO.1-puro-shEphA2-2
(CCGGGATAAGTTTCTATTCTGTCAGCTCGAGCTGACAGAATAGAAACTTATCTTTTT
TG), pLKO.1-puro-shEphA2-5
(CCGGTCGGACAGACATATAGGATATCTCGAGATATCCTATATGTCTGTCCGATTTTT
G) and scramble control were purchased from Millipore Sigma. Lentiviral particles were
produced in HEK293 cells. Cells were selected with puromycin (1 μg/mL).
JAK1 Knockdown Experiment
Knockdown of JAK1 in HCC cell lines was performed using siRNA. siGENOME
SMARTpool siRNA targeting JAK1 (CCACAUAGCUGAUCUGAAA;
UGAAAUCACUCACAUUGUA; UAAGGAACCUCUAUCAUGA;
GCAGGUGGCUGUUAAAUCU) was purchased from Dharmacon/Horizon, and transfected
into HCC cells at a concentration of 100 nM using Lipofectamine RNAiMAX reagent (ThermoFisher, #13778075) prepared in OptiMEM (Thermo-Fisher, #31985070) according to
manufacturer’s protocol. After 48 hours, knockdown efficiency was assessed by Western blot.
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Cell Viability Assays
HCC cell lines acquired from American Type Culture Collection (ATCC®) or the
Japanese Cancer Research Resources Bank (JCRB) were cultured in DMEM or RPMI 1640
supplemented with 10% fetal bovine serum (Tissue Culture Biologicals),
1×penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO) at 37°C and 5% CO2.
ALW-II-41-27 Experiment
For IC50 of ALW-II-41-27(ALW) studies, HCC cells were seeded into 96‐well plates
(5×103 cells/well). After 24 hours, cells were treated with 0, 0,25, 0.5, 1, 2, or 4μM of ALW.
After 48 hours, culture media was removed and alamarBlue (BUF012A; BioRad, Hercules, CA)
solution (1:10 dilution in DMEM) was added to the cells. After a 4 hours of incubation at 37°C,
fluorescence values were measured with a fluorescent plate reader at 530‐560 nm excitation/590
nm emission.
Cell Proliferation Experiments
For cell proliferation studies, HCC cells were seeded into 96‐well plates (5×103
cells/well). At indicated time points, culture media was removed and alamarBlue (BUF012A;
BioRad, Hercules, CA) solution (1:10 dilution in DMEM) was added to the cells. After a 4hours-incubation at 37°C, fluorescence values were measured with a fluorescent plate reader at
530‐560 nm excitation/590 nm emission.
High Resolution Hepatic Ultrasound
Hepatic ultrasound was performed using micro-ultrasound system (Vevo 2100,
Visualsonics) with 40 MHz ultrasound transducer (MS550D, Visualsonics) by the Small Animal
Core Facility at Loyola University Chicago Health Sciences Division.
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RNA Isolation, RNA Sequencing, Dataset Analysis, and QPCR
All total RNA was extracted using RNeasy Plus Mini Kit (Qiagen) following the
manufacturer’s protocol.
RNA Sequencing
RNA-seq was performed by Novogene Corporation and analyzed by Dr. Jun Li from the
University of Notre Dame. All RNA sequencing data produced in this study is deposited in Gene
Expression Omnibus, accession number: GSE141880. Gene set enrichment analysis was
performed using GSEA software (Broad MIT, http://www.gsea-msigdb.org/gsea/index.jsp).
HCC Patient mRNA Expression
All RNA expression data from The Cancer Genome Atlas Liver Hepatocellular
Carcinoma cohort was analyzed using Gene Expression Profiling Interactive Analysis (GEPIA;
http://gepia.cancer-pku.cn/)(Tang et al., 2017).
QPCR
For qPCR, 1 μg of RNA was reverse transcribed with iScript™ cDNA Synthesis Kit
(Bio-Rad). qRT-PCR was performed with iTaq Universal SYBR Green Supermix (Bio-Rad) on
the Real-Time PCR System. Primer pairs were selected from the Primer Bank
(https://pga.mgh.harvard.edu/primerbank/). Relative expression values for each gene of interest
were obtained by normalizing to GAPDH mRNA expression using the ΔΔCt method. All primers
used in this study are detailed in Supplementary Table 1.
Proximity Ligation Assay
Proximity ligation assay (PLA) was performed using the Duolink® In Situ Red Starter
Kit Mouse/Rabbit (Millipore Sigma) according to the manufacturer’s instructions. In brief, cells
were seeded on an 8 well-Nunc™ Lab-Tek™ II CC2™ Chamber Slide System (Thermo Fisher)
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at 17.5x103/well overnight, then fixed with 4% paraformaldehyde for 30 min at room
temperature and washed in PBS, followed by permeabilization with 0.1% Triton X-100 for 10
min. After washing with Wash Buffer A (Millipore Sigma) followed by blocking with Duolink
Blocking Buffer (Millipore Sigma) for 30 min at room temperature, cells were incubated with
primary antibodies (EphA2, 1:200 Santa Cruz and JAK1, 1:100, Cell Signaling) overnight at
4°C. On the next day, cells were washed repeatedly in Wash Buffer A, followed by incubation
with appropriate Duolink secondary antibodies (Millipore Sigma) for 1 hour at 37°C according
to the manufacturer’s protocol. After washing with Wash Buffer A at room temperature, ligation
and amplification steps of the PLA were performed according to the manufacturer’s protocol.
After final washes with Wash Buffer B at room temperature, slides were mounted with
Corning® 24x50 mm Rectangular #1 Cover Glass (Corning) using Duolink® In Situ Mounting
Medium with DAPI (Millipore Sigma).
EFNA1-fc Experiment
Stock solution of Recombinant Human Ephrin-A1 Fc Chimera Protein (R&D Systems;
EFNA1-fc) was prepared in PBS at 100 μg/mL and diluted to 0.1 μg/mL in DMEM based culture
medium. After HCC cells were seeded in a 6-well-culture plate 1.7x105/well overnight, the
medium was removed and the cells were treated with 0.1 μg/mL EFNA1-fc for 0, 2, 4, 8, 12, 16,
24, or 32 hours. Cell lysates were collected at these experimental times and analyzed by Western
blot.
Quantification and Statistical Analysis
Statistical tests used is indicated in the figure legends. Student’s t-test (unpaired, twotailed) was used to assess significance between experiment and control groups. One-way
ANOVA was used to determine if there is statistical significance between multiple experiment
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groups. Log rank test was used to assess the significance of differences in survival between
control and EphA2 knockout group. Chi-squared test was used to determine the significance of
correlations in TMAs. p < 0.05 was considered significant. plots and statistical analyses were
done using Prism version 7 software (GraphPad) and Excel.

CHAPTER FOUR
RESULTS
High EphA2 Signaling and Expression is Detected in HCC Patient Samples and is
Associated with Poor Prognosis
Cancer is a highly heterogeneous and complex disease, which makes understanding its
pathogenesis and the consequent development of an effective therapy immensely challenging. In
a valiant effort to tackle this challenge, The Cancer Genome Atlas (TCGA) has collected more
than 11,000 cases across 33 tumor types in the past decade and established a huge and
comprehensive databank mapping the molecular changes that occur in cancer in relation to
clinical outcome (Hutter & Zenklusen, 2018). To begin the assessment of EphA2’s role in HCC,
literature review revealed that EphA2 and its ligands were found to be highly correlated to
disease progression and poor clinical outcome in two independent studies of East-Asian HCC
cohorts (Cui et al., 2010; Wada et al., 2014). To confirm my suspicion that EphA2 signaling
promotes HCC, I queried the HCC-TCGA database to determine whether the mRNA expression
of EphA2 and its ligand correlate to patient’s overall survival. I found that high mRNA
expression of EphA2 in The Cancer Genome Atlas (TCGA) human HCC dataset was associated
with poor prognosis (Figure 3), and that 4 out of 5 EphA2 ligands (EFNAs) are highly expressed
in HCC compared to normal liver tissue and are associated with significantly worse clinical
outcome (Figure 5).
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Figure 3. Kaplan-Meier Plot of Overall Survival of 362 HCC Patients Stratified by
EphA2 Expression Levels from TCGA Database (GEPIA). Hazard ratio of = 1.4. Statistical
significance was determined by Log-rank test (p = 0.049).
Since it has been established that transcript levels do not necessarily correlate to protein
expression levels (Liu, Beyer, & Aebersold, 2016). I aimed to directly measure EphA2 forward
signaling activity in human HCC. Previous studies showed that phosphorylation at the
juxtamembrane domain tyrosine 588 position of EphA2 (Y588 p-EphA2) is essential for its
signaling activity (Binns, Taylor, Sicheri, Pawson, & Holland, 2000; Fang, Brantley-Sieders,
Hwang, Ham, & Chen, 2008). To explore the role of EphA2 signaling in HCC, I performed
Y588 p-EphA2 and total EphA2 immunohistochemistry on liver tissue microarrays from a
retrospective cohort of 153 HCC and 63 normal patients. Y588 p-EphA2 and total EphA2
protein levels were assessed by a hepatic pathologist blinded to patient outcome (Figure 4). High
expression of Y588 p-EphA2 and total EphA2 was detectable in 33.33%, and 30.06% of HCC
cases respectively (Figure 4B and 4C), while in normal patients, high p-EphA2 and EphA2
expression was only detectable in 4.76% and 9.52% of cases respectively.
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Theimmunohistochemistry result shows that high expression of both p-EphA2 and total EphA2
correlates with HCC pathology (Figure 4A-C).
A.

B.

C.

D.

Figure 4. High EphA2 Signaling and Expression is Detected in Livers of HCC Patients
Compared to Normal. (A) Representative IHC of normal vs HCC TMAs (B) Y588 p-EphA2
expression levels in TMAs of normal and HCC liver samples. (C) Total EphA2 expression
levels in TMAs of normal and HCC liver samples. (D) Representative immunohistochemistry
(IHC) images of Y588 p-EphA2 and total EphA2 in HCC tissue microarray classified as
Negative, Low or High expression. Scale bars, 500 μm. Scale bars, 500 μm. Statistical
significance was determined by chi-squared test (B) and (C).
Furthermore, high mRNA expression of EphA2 in The Cancer Genome Atlas (TCGA)
human HCC dataset was associated with poor prognosis (Figure 3). Because Ephrin A class
ligands (EFNAs) are known to activate EphA2 signaling (Boyd, Bartlett, & Lackmann, 2013;
Kania & Klein, 2016; Pasquale, 2010), I also analyzed the expression of EFNAs in the TCGA
HCC dataset and found that 4 out of 5 EFNAs are highly expressed in HCC and are associated
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with poor prognosis (Figure 5). Collectively, these data suggest that high EphA2 signaling and
expression are correlated with HCC pathology and worse clinical outcomes for patients.

Figure 5. EphA2 Ligands (EFNAs) are Highly Expressed in HCC Compared to Normal Liver Tissue and are
Associated with Significantly Worse Prognosis. Upper, boxplot of relative mRNA expression levels of EFNAs
comparing normal vs HCC tissue. Bottom, Kaplan-Meier plot of overall survival of HCC patients stratified by EFNA
expression levels. 4/5 EFNAs (EFNA1, 3, 4 &5) reached statistical significance, determined by two-tailed Student’s
t-test *p < 0.0001 boxplot and log rank test Kaplan-Meier plot. Data from TCGA (GEPIA) *p < 0.0001
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EphA2 Drives HCC Tumor Growth and Survival
After establishing the clinical relevance of EphA2 and its ligands in HCC, I sought to
test the functional role of EphA2 signaling in HCC. To identify proper models for mystudy, first,
I assessed EphA2 expression and activity in 7 human HCC cell lines and found that all expressed
EphA2 and Y588 p-EphA2 with varying degrees (Figure 6). Interestingly, phosphorylation of the
EphA2 at the serine 897 position (S897), which indicates AKT and non-ligand dependent
activation of EphA2 (H. Miao et al., 2015; Hui Miao et al., 2009), was also notable in these
human HCC cells lines (Figure 6). In particular, Huh7 and SNU449 showed the highest nonligand dependent signaling.

Figure 6. EphA2 Expression and Signaling Level in 7 Human HCC Cell Lines. Western
blot showing EphA2 activation in 7 independent HCC cell lines. Y588 marks for ligand
dependent activation while S897 marks for the AKT and non-ligand dependent activation of
EphA2. GAPDH as loading control.
If EphA2 signaling plays an important role in hepatocarcinogenesis, I hypothesized that
inhibition of EphA2 in HCC cells with high EphA2 expression or signaling will significantly
suppress tumor growth and progression. Therefore, I selected two human HCC cell lines with
high levels of p-EphA2 and EphA2 expression (Huh7 and Hep3B), and attenuated the expression
of EphA2 by lentiviral-shRNA knockdown (Figure 7A). Immunoblot of EphA2 knockdown vs
scramble control HCC cells confirmed substantial decrease in signaling and expression of EphA2
(Figure 7A). To determine how EphA2 affects HCC cell death and survival, I examine the
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expression level of poly ADP-ribose polymerase-1 (PARP1) and cleaved-Caspase 3 in EphA2
knockdown cells compared to scramble control. PARP1 is an enzyme that facilitates nucleotide
excision repair, and its unique cleaved fragments are crucial biomarkers for cell death including
apoptosis (Chaitanya, Steven, & Babu, 2010). Similarly, caspase 3 is an essential executioner of
apoptosis and it’s activated through proteolytic cleavage into p17 and p12 fragments (Nicholson
et al., 1995).
A.

B.

C.

Figure 7. EphA2 Knockdown Promotes Apoptotic Cell Death and Impairs Growth of
HCC Cells. (A) Western blot validating EphA2 knockdown efficiency and measuring Caspase
3 activation and PARP cleavage after lentiviral transduction of 3 independent EphA2 shRNAs
7 days after puromycin selection GAPDH as loading control (B and C) Cell proliferation
studies of control vs EphA2 knockdown Huh7 and Hep3B cells at day 7 after puromycin
selection. Cell proliferation was evaluated using the alamar blue assay. Ratio of proliferation
is normalized to at 6 hours after initial seeding of the cells, and measure at 24, 48, and 72
hours. Values are mean± SD (n=4). **p < 0.01, ***p < 0.001 and ****p < 0.0001.
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Functionally, western blot showed EphA2 knockdown HCC cells exhibited significant Caspase 3
activation and subsequent PARP cleavage compared to scramble control, suggesting that EphA2
knockdown promotes apoptotic cell death in HCC (Figure 7A). In vitro growth assays showed
that knockdown of EphA2 impaired the proliferation of Huh7 and Hep3B cells (Figure 7B and
C). To verify the role of EphA2 in HCC in vivo, I established xenograft models with Huh7 cells
(control or shRNA-mediated suppression of EphA2). Following implantation of tumor cells at

Figure 8. EphA2 knockdown Suppresses Tumor Development in Xenograft Model of
HCC. Left, representative picture of NSG-A2 mice 28 days after injection with 3*106 Huh7
cells. Left flank: shCtrl. Right Flank: shEphA2. n = 3 mice per group. Right, daily
measurements of primary tumor size. Values are mean± SEM. Statistical significance was
determined by two-tailed Student’s t test. *p < 0.05
day 0, controls showed first sign of tumor at ~18 days, and an exponential increase in tumor
volume during the subsequent week. In contrast, EphA2 knockdown mice showed no sign of
tumor for up to 28 days (Figure 8). Together, my result suggested that EphA2 is crucial for
tumor proliferation and survival in HCC.
EphA2 Drives Self-Renewal and Tumor Initiation in HCC
To explain the significant tumor suppression in the EphA2 knockdown observed in the in
vivo model of HCC, I turned to our RNA sequencing data of EphA2 knockdown Huh7 cells and
found that gene sets pertinent to mesenchymal stem cells, liver cancer recurrence, and poor

52
clinical outcomes for HCC patients were significantly downregulated compared to the scramble
control (Figure 9A-C).
A.

B.

C.

D.

Figure 9. EphA2 Promotes the Expression of Tumor Initiating Factors and Correlates to
Liver Cancer Reoccurrence and Poor Survival in Patients. Gene set enrichment analysis
reveals that genes important for (A) mesenchymal stem cell, (B) liver cancer recurrence and
(C) poor survival in HCC patient are suppressed in EphA2 knockdown Huh7 cells compared
to scramble control. (D) qPCR analysis of the indicated gene expression in EphA2 knockdown
Huh7 cells compared to scramble control. Values are mean± SD (n=3). Statistical significance
was determined by two-way ANOVA with Sidak's multiple comparisons test. *p < 0.0001
Subsequent, qPCR further confirmed that the expression of known tumor-initiating, and
embryonic stem cell markers including SOX2, KLF4, NANOG, LIN28A were all suppressed
after the knockdown of EphA2 (Figure 9D). EPCAM, a clinically relevant biomarker for HCC
(Yamashita et al., 2009), is also significantly suppress in EphA2 knockdown and positively
correlated with EphA2 expression in HCC cells (Figure 9D and 10).
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Figure 10. EphA2 Expression is Positively Correlated with HCC Biomarker EPCAM.
Hep3B cells stained with the indicated antibodies and gated according to EphA2 (PE) and
EPCAM (FITC) levels.
My previous data showed that EphA2 knockdown was able to significantly halt
tumorigenesis in xenograft model of HCC (Figure 8). It’s important to determine under nonartificially perturbed condition whether EphA2 can promote self-renewal and tumor-initiation of
HCC in vivo. To answer this question, I employed the in vivo limiting dilution method, as it has
been established as a hallmark experiment for determining the presence of tumor initiating cells.
The capacity of a given cell population to initiate a tumor at limited concentrations in mice is
interpreted as frequencies of tumor-initiating cells (Batlle & Clevers, 2017; Singh et al., 2004)
EphA2 expression profile in a population of Huh7 cells were assessed using flow cytometry. The
top 15% of EphA2 expressing cells were sorted into high EphA2 group (EphA2 high), while the
low 15% EphA2 expression cells were sorted into the low EphA2 group (EphA2 low) (Figure
11A).
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Cells were then xenografted to 8 weeks old NSG mice, and the tumors incidents, latency and
growth were recorded for EphA2 hi and EphA2 lo Huh7 cells (Figure 11B-C). My results
suggest that EphA2 plays an important role in regulation of self-renewal and tumor initiation in
HCC.
A.

B.

C.

Figure 11. EphA2 Promotes HCC Tumor Initiation In Vivo. (A) Huh7 Cells were sorted
and gated according to EphA2 levels (Top 15%, high; low 15%, low) (B) Representative
image of tumor development of EphA2 high vs low Huh7 cells. (C) NSG-A2 mice were
injected with EphA2 high or low human HCC cells at the indicated dose. Tumor incidence and
latency were monitored and recorded.
Targeting EphA2 Significantly Suppresses Tumor Initiation and Progression, and
Enhances Overall Survival in MET/CAT Induced Murine Model of HCC
Our lab has previously utilized several established genetically engineered mouse models
(GEMM) of HCC to study hepatocarcinogenesis (Shang et al., 2015; Shang et al., 2019; Wang et
al., 2018). The advantages of the GEMM model are: (1) tumor develops at its site of origin and
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retains its native vasculature and microenvironment; (Finn et al., 2019) mice are
immunocompetent; and (El-Khoueiry et al., 2017) mice exhibit comparable clinical symptoms
such as hepatomegaly and ascites. I specifically chose the MET/CAT model because it is driven
by two well-established human HCC oncogenes, c-MET and β-Catenin, that are co-activated in 9
– 12.5% of human HCCs (Cieply, Zeng, Proverbs-Singh, Geller, & Monga, 2009; Kaposi-Novak
et al., 2006; Tao et al., 2016; Tward et al., 2007). Furthermore, a previous transcriptome study of
675 human cancer cell line that suggests EphA2 is strongly correlated with c-MET expression
(Klijn et al., 2015), and β-Catenin is also reported to enhance EphA2 expression via c-MYC
(Peng et al., 2018). I found that Both p-EphA2 and EphA2 are highly expressed in MET/CAT
driven HCC tumors (Figure 12A). To study the role of EphA2 in this model, I combined the
MET/CAT model with CRISPR-Cas9 mediated inhibition of EphA2 expression in the mouse
liver (Cong et al., 2013; Xue et al., 2014). First, I cloned three pX330 vectors, each coexpressing Cas9 and 1 of 3 independent sgRNA selected to target EphA2.
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A.

C.

B.

D.

E.

Figure 12. In Vivo CRISPR Targeting EphA2 Effectively Suppresses EphA2 Expression
in Murine Liver Model of HCC. (A) Western blot validating MET/CAT HCC model, and
analyzing for EphA2 signaling and expression 10 days after injection. ACTIN as loading
control. (B) Schematic of the experiment of targeted inhibition of EphA2 in MET/CAT
induced murine HCC model. pX330 plasmids expressing Cas9 and sgRNA targeting EphA2
(sgEphA2) or empty vector (PX330) were hydrodynamically delivered to mice liver in
conjunction with MET/CAT; mice were observed for development of HCC for 8 – 9 weeks.
n=6 mice in PX330 group, and n=9 mice in sgEphA2 group. (C) Efficacy of 3 independent
sgEphA2 constructs were validated by IHC in MET/CAT model 10 days after injection. Scale
bars, 100 μm. (D) Western blot confirming the efficacy of sgEphA2-2 in MET/CAT model 10
days after injection. GAPDH as loading control. (E) Immunofluorescence analyzing EphA2
knockout in the context of MET overexpression in MET/CAT model 10 days after injection.
EphA2 (green), c-MET (red). Nuclei were stained with DAPI (blue). Scale bars, 30 μm.

57
Next, to simultaneously knockout EphA2 in the context of MET/CAT-induced HCC, I
hydrodynamically injected age-and-gender-matched C57BL/6J mice with plasmids encoding (1)
the Sleeping Beauty transposase (HSB2), (Finn et al.) transposons with MET/CAT oncogenes,
and (El-Khoueiry et al.) the PX330-CRISPR cassette co-expressing sgEphA2 and Cas9 or just
Cas9 (Figure 12B). Immunoblot confirmed successful delivery of c-MET and β-Catenin in the
mouse livers (Figure 12A). Of the three sgEphA2 constructs tested, sgEphA2-2 was chosen for
further experiments because of its high knockout efficacy (Figure 12C). The efficacy and
specificity of sgEphA2-2 was further validated using immunoblot and immunofluorescence, as I
showed that c-MET expression in empty vector and sgEphA2 treated livers were comparable,
and EphA2 expression was lost only in c-MET overexpressing liver cells (Figure 12D and 12E).
I previously showed that hydrodynamic injection delivered c-MET and β-Catenin equally into
the same cells (Shang et al., 2015); thus, the results suggest that EphA2 expression was
attenuated by sgEphA2-2 in the MET/CAT induced HCC model.
For the full experiment, age-and-gender-matched C57BL/6J mice were divided into 2
groups: one received MET/CAT + pX330 control, while the other received MET/CAT+
sgEphA2-2. On day 45 after the injection, mice were sacrificed, and their livers were collected
and analyzed. Notably, mice receiving sgEphA2-2 had significant reduction of tumor burden
compared to the pX330 control, while the control mice developed ascites, hepatomegaly and
tumor mass (Figure 13A and 13B). In situ-high resolution ultrasound on day 55 showed that
sgEphA2 treated mice demonstrated long-term effective suppression of HCC development as
demonstrated by the absence of prominent tumor mass (Figure 13C).
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A.

B.

C.

Figure 13. Targeting EphA2 Significantly Suppresses Tumor Development in MET/CAT
Induced Murine Model of HCC. (A) Upper, representative image of mouse abdomen in
MET/CAT mouse treated with PX330 or sgEphA2 45 day after injection. Bottom, gross image
of livers extracted from mice from the upper panels. Livers were analyzed for HCC
development; tumor incidence and liver weight were recorded. (B) Liver to body weight ratios
were calculated for MET/CAT mice injected with PX330 or sgEphA2 for 8 weeks (56 days). n
= 3 mice per group. (C) Top, representative 2D liver ultrasound image of wild type mice
(untreated), PX330 and sgEphA2 injected MET/CAT mice 55 days after injection. Middle, 3D
reconstruction mice liver. Prominent hyperechoic tumor mass (red arrow) surrounded by
necrotic and hemorrhagic cysts. Bottom, gross representation of the mice livers. Statistical
significance was determined by two-tailed Student t test ****p < 0.0001.
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B.

C.
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Figure 14. Targeting EphA2 Significantly Suppresses Tumor Progression and Enhances
Overall Survival in MET/CAT Induced Murine Model of HCC. (A) Livers of MET/CAT
mice injected with PX330 or sgEphA2 were collected at day 45 for H&E, and
immunohistochemistry for HCC and proliferative markers, AFP and Ki67 respectively. Scale
bars, 100 μm. (B) Kaplan-Meyer plot for experiment illustrated in (B) representing percent of
survival (y-axis) at days elapsed after injection (x-axis). (C) Liver of sgEphA2 MET/CAT mice
was extracted 55 day after injection and immunohistochemically assessed for total EphA2
expression. There are multiple microscopic foci of dysplastic hepatocyte nodules stained
positive for EphA2. On the other hand, the non-dysplastic background liver hepatocytes are
negative for EphA2. Notably, there dysplastic foci are associated with strong EphA2
expression characterized by nuclear crowding, enlarged hyperchromatic nucleus and frequent
mitotic bodies (white arrows) which is consistent with early HCC. Scale bar, 50 μm. (D) Liver
of sgEphA2 MET/CAT mice described in (A) was collected for H&E and
immunohistochemistry for EphA2 and AFP (HCC marker). Scale bar, 50 μm. Statistical
significance was determined by log rank test.
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Microscopic examination of pX330 control livers showed hallmark HCC features,
including increased cellular density, nuclear polymorphism, vesicular chromatin, and intratumor
and extramedullary hematopoiesis with nucleated red blood cells (Figure 14A).
Immunohistochemical staining for alpha-fetoprotein (AFP), a common HCC marker, was
dramatically lower in the livers of sgEphA2-2 mice compared to PX330 control mice (Figure
14A). Importantly, all of the PX330 control mice died with advanced liver cancer within 37‐65
days, while sgEphA2-2 mice developed tumor at long latency, as 45% of the mice were
symptom-free and were still alive beyond 106 days (Figure 14B). Intriguingly, sgEphA2-2 mice
that eventually developed HCC had re-expression of EphA2 in the tumor region. This suggests
that deletion of EphA2 was incomplete resulting in eventual initiation and development of longlatency tumors in these mice (Figure 14C and 14D). Taken together, my results demonstrate that
EphA2 is an important promotor for the initiation and development of MET/CAT driven HCC.
EphA2 Promotes Development of HCC Partially Through Activation of the AKT Pathway
To investigate the underlying mechanism of EphA2 induced tumor development in HCC,
RNA sequencing was performed on EphA2 knockdown and scrambled control Huh7 cells. Gene
set enrichment analysis revealed that genes induced by AKT signaling were significantly
enriched in the control cells compared with EphA2 knockdown cells (Figure 15A). Previous
studies demonstrated that the modality of EphA2 regulation of AKT is highly variable and tissue
dependent; that is, ligand induced EphA2 signaling can either activate or inhibit AKT under
different conditions (Chang, Jorgensen, Pawson, & Hedley, 2008; Hui Miao et al., 2009;
Pasquale, 2010).
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Figure 15. EphA2 Promotes Initiation and Growth of HCC Partially Through Activation
of AKT Pathway. (A) Gene set enrichment analysis reveals that genes in the AKT pathway
are highly enriched in EphA2 knockdown Huh7 cells. (B) Cell lysate of EphA2 knockdown
Huh7 and Hep3B cells was immunoblotted for p-AKT, and total AKT. GAPDH as loading
control. (C) Western blot validating overexpression of constitutively-active AKT (CA-AKT)
in the context of two independent shRNA mediated EphA2 knockdown in Huh7 cells.
GAPDH as loading control. (D) Cell proliferation study was conducted using cells described
in (C) using the alamar blue assay. Fluorescence intensity was measured at day 0 (6 hours after
seeding), and subsequently at day 2, 4, and 6 hours. Values are mean± SD (n=4). (E)
representative picture of tumors extracted from NSG-A2 mice 28 days after subcutaneous
injection with cells described in (C) and (D). n=4, 6, 9 mice in shCtrl + EV, shEphA2 + EV,
shEphA2 + CA-AKT respectively. (F) daily measurements of primary tumor size. Values are
mean± SEM.
Statistical significance was determined by two-tailed Student t test (D) and one-ANOVA
analysis with Dunnett's multiple comparisons test (F) **p < 0.01, ***p < 0.001 and ****p <
0.0001.
In line with our RNA-sequencing data, I found that AKT signaling was substantially
suppressed in both Huh7 and Hep3B EphA2 knockdown cells compared with the scrambled
control (Figure 15B). Similarly, knocking out EphA2 decreased AKT activity in our MET/CAT
model of HCC (Figure 27B and 27C). Interestingly, the degree of suppression of AKT signaling
correlated strongly with the efficacy of EphA2 knockdown (Figure 15B). Overall, these data
suggest that EphA2 promotes AKT signaling in the context of HCC. To further validate my
hypothesis regarding the relationship between EphA2 and AKT in HCC, I expressed a
constitutively active form of AKT (CA-AKT) in the context of EphA2 knockdown in Huh7 cells
(Figure 15C). Expression of CA-AKT rescued the proliferation of EphA2 knockdown cells in
vitro (Figure 15D). Intriguingly, when tumor cells were implanted in the HCC xenograft model,
expression of CA-AKT only partially rescued tumor growth in EphA2 knockdown cells (Figure
15E). Taken together, the results suggest that EphA2 drives the development of HCC partially
through AKT signaling.
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EphA2 Drives HCC Tumor Development Partially Through Activation of STAT3
Signaling
Because expression of CA-AKT was only able to partially rescue tumor development in
EphA2 knockdown cells in the HCC xenograft model, I suspected that additional signaling
pathways may be involved in EphA2 signaling. Turning again to our RNA-sequencing data, I
found the JAK/STAT3 pathway is the second most enriched pathway in the scrambled control
cells compared with EphA2 knockdown (Figure 16A), suggesting that STAT3 is a downstream
target of EphA2 in HCC. I took a specific interest in STAT3 for a few reasons. First, it is wellestablished that STAT3 is a crucial oncogene that promotes tumor initiation and progression in a
majority of human malignancies (Huynh, Chand, Gough, & Ernst, 2019; Johnson, O'Keefe, &
Grandis, 2018; Yu, Lee, Herrmann, Buettner, & Jove, 2014). Second, STAT3 is often
hyperactivated in human HCC correlating to more aggressive tumor and poor clinical outcomes
for patients (Calvisi et al., 2006; He & Karin, 2011; He et al., 2010). Third, STAT3 signaling
promotes stem-cell like properties in cancers by transcription of key pluripotent factors such as
SOX2 and KLF4, leading to tumor initiation, relapse, and drug resistance (Hall et al., 2009;
Huynh et al., 2019; Schroeder et al., 2014; Yu et al., 2014). While a previous study showed that
EphA2 acts as a crucial pathogen recognition receptor against fungal infection that promotes
inflammation by increase in JAK2/STAT3 signaling (Swidergall, Solis, Lionakis, & Filler,
2018), no study has reported that EphA2 signaling can activate STAT3 in cancer. To further
explore this possibility, I knocked down EphA2 in Huh7 and Hep3B cells and found that
phosphorylation of STAT3 at Tyr705, which is critical for activation of STAT3 (Darnell, Kerr,
& Stark, 1994), is suppressed (Figure 16B). Similarly, knocking out EphA2 attenuated STAT3
activity in our MET/CAT HCC model (Figure 16C, 27B and 27C). These results provide
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evidence that STAT3 is a downstream effector of EphA2 signaling. Previous studies showed that
STAT3 can be an important downstream effector of AKT signaling (Abdelhamed, Ogura,
Yokoyama, Saiki, & Hayakawa, 2016; Yokogami, Wakisaka, Avruch, & Reeves, 2000). To test
this possibility, I evaluated the activity of STAT3 signaling in control, shEphA2, and shEphA2 +
CA-AKT Huh7 cells by immunoblot. Interestingly, overexpression of CA-AKT did not affect
STAT3 signaling in shEphA2 cells (Figure 16D).
A.

C.

B.

D.

Figure 16. Inhibition of EphA2 Suppresses the Activation of STAT3 in HCC. (A) Gene set
enrichment analysis reveals that genes in the JAK/STAT3 pathway are highly enriched in
EphA2 knockdown Huh7 cells. (B) Cell lysate of EphA2 knockdown Huh7 and Hep3B cells
was immunoblotted for p-STAT3, and total STAT3. GAPDH as loading control. (C) Liver of
EphA2 knockout MET/CAT mice were extracted and immunohistochemically assessed for pSTAT3 expression comparing to control (PX330). Scale bar, 100 μm. (D) Cell lysate of
EphA2 knockdown Huh7 cells with overexpression of CA-AKT was immunoblotted for pSTAT3, and total STAT3. GAPDH as loading control.
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Figure 17. EphA2 Drives Tumor Initiation and Development Partially Through
Activation of STAT3 Signaling. (A) Western blot validating overexpression of STAT3 in the
context of shRNA mediated EphA2 knockdown in Huh7 cells. GAPDH as loading control.
(B) Cell proliferation study was conducted using cells described in (A) using the alamar blue
assay. Ratio of proliferation calculated by normalizing fluorescent intensity to at day 0 (6
hours after seeding of the cells), and subsequently measured at day 1, 2, and 4 days. Values are
mean± SD (n=4). (C) Representative picture of tumors extracted from NSG-A2 mice 28 days
after subcutaneous injection with cells described in (A) and (B). n=4 mice in each group. (D)
primary tumor size was recorded every two days. Values are mean± SEM. (E) qPCR analysis
of the indicated gene expression in cells described in (A) and (B). Values are mean± SD (n=3).
Statistical significance was determined by one-ANOVA analysis with Tukey's multiple
comparisons test (B) and (D) and two-tailed Student t test (E). NS, not significant; *p < 0.05,
**p < 0.01, ***p < 0.001 and ****p < 0.0001.
Furthermore, I overexpressed STAT3 in EphA2 knockdown Huh7 cells by lentiviral transduction
(Figure 17A). Surprisingly, STAT3 overexpression had no effect on the proliferation of Huh7
cells in the context of EphA2 knockdown in vitro (Figure 17B). However, in the Huh7 xenograft
model, overexpression of STAT3 significantly rescued and initiated tumor growth in the EphA2
knockdown condition, as tumor initiation was observed on day 16 after implantation compared to
the shEphA2 where no tumor was observed on day 28 (Figure 17C). Adding to this result, a
repertoire of tumor initiating and pluripotent factors that were suppressed in the EphA2
knockdown was dramatically rescued by STAT3 overexpression (Figure 17D). Overall, these
results show that EphA2 drives tumor development through the activation of STAT3.
Combined Overexpression of Constitutively Active AKT and STAT3 Completely Rescues
Tumor Growth in EphA2 Knockdown HCC Cells In Vivo
To investigate the significance of AKT and STAT3 pathway in EphA2 induced
hepatocarcinogenesis, I expressed constitutively active AKT (CA-AKT) in combination with
STAT3 in the context of EphA2 knockdown in Huh7 cells (Figure 18A). Importantly, combined
overexpression of CA-AKT and STAT3 (DR) completely rescued tumor growth in the EphA2
knockdown condition compared to either alone, and there is no significant difference between
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tumor growth of DR and control Huh7 cells (Figure 18B). My result suggests that AKT and
STAT3 pathways are the main downstream effectors for EphA2 induced tumorigenesis in HCC.
EphA2 Activates STAT3 Signaling via JAK1 in HCC
A.

B.

Figure 18. Combined Overexpression of AKT and STAT3 Completely Rescues Tumor
Development in EphA2 Knockdown HCC Cells. (A) Western blot validating the combined
overexpression of CA-AKT and STAT3 in the context of shRNA mediated EphA2 knockdown
in Huh7 cells. GAPDH as loading control. (B) At day 0, NSG-A2 mice were subcutaneously
engrafted with 3*106 of shCtrl, shEphA2, shEphA2+CA-AKT, shEphA2+STAT3 or
shEphA2+DR Huh7 cells. Tumor size was measured every 2 days of primary tumor size.
Values are mean± SEM. n = 4 mice per group.
Next, I investigated how EphA2 activates STAT3 in HCC. JAK family non-receptor
tyrosine kinases (JAKs) can directly activate STAT3 through canonical activation of STAT3 in
many malignancies including HCC (Johnson et al., 2018; Yu et al., 2014). Previous studies
showed that when activated by ligands, receptor tyrosine kinases such as EGFR, PDGFR, and
FGFR, can activate JAKs (Andl et al., 2004; Huynh et al., 2019). This led us to test whether
EphA2 activates STAT3 via JAKs. RNA-seq data showed that JAK1 had substantial expression
in HCC cells while the expression of JAK2 was modest and the expression of JAK3 was very
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low (Figure 19A).
A.

B.

C.

D.

Figure 19. Inhibition of EphA2 Suppress the JAK1/STAT3 Pathway in HCC. (A)
Normalized RNA expression of JAK1, JAK2 and JAK3 in scramble (shCtrl) or EphA2
knockdown Huh7 cell (n=3). (B) Western blot confirmation of JAK2 expression in Huh7 cells.
K562 as positive control. GAPDH as loading control. (C) Cell lysate of EphA2 knockdown
Huh7 and Hep3B cells was immunoblotted for p-JAK1, JAK1, p-STAT3 and total STAT3.
GAPDH as loading control. (D) Liver of EphA2 knockout MET/CAT mice were extracted and
immunohistochemically assessed for p-JAK1 expression comparing to control (PX330). Scale
bar, 100 μm.
I further confirmed that little if any JAK2 protein expression was detected in HCC cells by
immunoblot (Figure 19B). I therefore examined if EphA2 can activate JAK1 in HCC cells.
Phosphorylation of JAK1 at Tyr1034/1035, which is critical for activation of JAK1 (Leonard &
O'Shea, 1998), was suppressed when EphA2 was knocked down in both Huh7 and Hep3B cells
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(Figure 19C). Suppression of JAK1 phosphorylation was associated with substantially lower
STAT3 activation compared to the scramble controls (Figure 19C). Knocking out EphA2 in the
MET/CAT model of HCC also suppressed JAK1 activation (Figure 19D, 27C and 27D).
Furthermore, I knocked down JAK1 in both Huh7 and Hep3B using small interfering
RNA (siRNA) and found that STAT3 signaling was attenuated by JAK1 siRNA compared with
control siRNA (Figure 20A). Moreover, treatment with a JAK inhibitor (JAK-Inhibitor-I
(Thompson et al., 2002)) potently inhibited STAT3 signaling in Huh7 cells (Figure 20B). To
myknowledge, no previous study has shown that EphA2 can activate the JAK/STAT3 pathway
in cancer. A previous study did show that EphA4, another member of Ephrin receptor family,
can directly interact with JAK2 and activate STAT3 signaling at the neuromuscular junction (Lai
et al., 2004), raising the possibility that other Eph receptor family members such as EphA2 can
activate STAT3 in a similar manner. Notably, using proximity ligation assay (PLA) (Söderberg
et al., 2006; Weibrecht et al., 2010) , I found notable interaction between EphA2 and JAK1 in the
scramble control HCC cells that was significantly reduced in the EphA2 knockdown (Figure
20C). Taken together, these results indicate that EphA2 promotes STAT3 signaling through
activation of JAK1.
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A.

B.

C.

Figure 20. EphA2 Activates STAT3 Signaling via JAK1 in HCC. (A) Huh7 and Hep3B
cells were transfected with siRNA targeting JAK1. 48 hours after the transfection, protein was
extracted and immunoblotted for JAK1, p-JAK1, p-STAT3, STAT3, p-AKT and AKT
expression. GAPDH as loading control. (B) Western blot analysis of indicated protein from
Huh7 cells treated with JAK inhibitor (P6) for 24 hours. GAPDH as loading control. (C) Left,
the interaction of EphA2 and JAK1 was quantified using proximity ligation assay (PLA) in
Huh7 scramble (shCtrl) and EphA2 knockdown (shEphA2) cells. Positive PLA interation
(red). Nuclei was stained with DAPI (blue). Scale 10 μm. Right, PLA Puncta per cell was
quantified using Imaris Bitplane. n=10. Statistical significance was determined by oneANOVA analysis with Tukey's multiple comparisons test (C). ns, not significant; *p < 0.05,
****p < 0.0001.
EphA2 Signaling is Positively Correlated with AKT and JAK1/STAT3 Activation in HCC
Patient Samples
Mydata shows that EphA2 promotes HCC initiation and development through activation
of both AKT and JAK1/STAT3 in cell based and animal models. To determine whether the
EphA2/AKT and EphA2/JAK1/STAT3 axes are relevant in human HCC, I examined p-EphA2,
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p-AKT, p-JAK1 and p-STAT3 by immunohistochemistry in a tissue microarray including 153
human HCC specimens. Notably, p-EphA2 expression was positively correlated with the
activation status of AKT, JAK1 and STAT3 within the same tumor region (Figure 21A-E). There
was a strong positive correlation between p-JAK1 and p-STAT3 expression, highlighting the
importance of JAK1 as an activator of STAT3 in HCC (Figure 21F). Taken together, these
results suggest that EphA2 activates both AKT and JAK1/STAT3 signaling in human HCC.
A.

B.

C.

D.
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E.

F.

Figure 21. EphA2 Signaling is Positively Correlated with AKT and JAK1/STAT3
Activation in HCC Patient Samples. (A) Representative immunohistochemistry (IHC)
images and correlation of Y588 p-EphA2, p-AKT, p-JAK1 and p-STAT3 in HCC tissue
microarray classified as Negative, Low or High expression. Scale bars, 500 μm. (B)
Representative high-power magnification of IHC images of HCC showing correlation between
Y588 p-EphA2, p-AKT, p-JAK1 and p-STAT3. Scale bar, 100 μm. (C – F) Correlation
analysis of all HCC TMA tissues between Y588 p-EphA2 and p-AKT (C), p-EphA2 and pJAK1 (D), Y588 p-EphA2 and p-STAT3 (E), and p-JAK1 and p-STAT3. Statistical
significance was determined by chi-squared test (C – F).
Pharmacologic Targeting of EphA2 Impairs Growth and Progression of HCC In Vitro and
In Vivo
So far, I have shown that the receptor tyrosine kinase-EphA2- is an important oncodriver
that promotes the initiation and progression of HCC. Given the success of targeting receptor
tyrosine kinases with specific small molecule kinase inhibitors (Ferguson & Gray, 2018), I next
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explored the translational potential of targeting EphA2 with the small molecule inhibitor ALWII-41-27 (ALW). ALW is a potent and selective EphA2 inhibitor, which was recently shown to
exhibit anti-tumor activity in several solid malignancies (Amato et al., 2014; Amato et al., 2016;
Choi et al., 2009; Martini et al., 2019). To test the effect of ALW on HCC, six human HCC cell
lines with substantial p-EphA2 expression were treated with increasing concentrations of ALW,
and the IC50s were calculated. ALW potently impaired the growth of all 6 HCC cell lines
(Figure 22A). Importantly, HCC sensitivity to ALW positively correlated with the expression of
p-EphA2 (Figure 22B). Consistent with the functional inhibition of EphA2 using
knockdown/knockout approaches, ALW effectively decreased the phosphorylation of EphA2 at
Y588 and its downstream effectors (p-AKT, p-JAK and p-STAT3) in HCC cells, indicating the
selective inhibition of EphA2 forward signaling (Figure 22C). To test the effect of ALW on HCC
in vivo, I treated mice from a human xenograft model of HCC with ALW and observed the
impact on tumor growth.
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A.

B.

ALW
Huh7 Hep3B SNU449 SNU387 SNU475 SNU423
IC50 (μM) 0.4629 0.651 0.8027
1.073
1.439 0.7946

C

E.

D
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Figure 22. Pharmacologic Targeting of EphA2 Impairs Growth and Progression of HCC
In Vitro and In Vivo. (A) The effect of ALW-II-41-27 on cell proliferation of 6 HCC cell
lines was assessed after 48 hours treatment using alamar blue assay. Data are shown as percent
of fluorescence comparing to DMSO control. Values are mean± SD (n=4). (B) Correlation
between Y588 p-EphA2 expression and sensitivity to ALW-II-41-27 in HCC cells described in
(A). (C) Western blot analysis of indicated proteins at selected time and concentration of
ALW-II-41-27 in Huh7, Hep3B and SNU449 cells. GAPDH as loading control. (D) Image of
tumors extracted from NSG-A2 mice subcutaneously injected with 5*106 Huh7 cells; 7 days
after treatment with 15mg/kg/day ALW-II-41-27 or vehicle. Treatment began after tumor
reached to 200 mm3. n=5 mice per group. Bottom, daily measurements of primary tumor size.
Values are mean± SD (E) Tumors from mice treated with ALW-II-41-27 or vehicle described
in (D) was collected for H&E and immunohistochemically assessed for Y588 p-EphA2, pAKT, p-JAK1 and p-STAT3 expression. Scale bar 100 μm. Statistical significance was
determined by two-tailed Student t test (D). ***p < 0.001.
Specifically, when tumors reached 200 mm3, mice were randomized into treatment groups, and
treated once daily with 15 mg/kg ALW or vehicle for 1 week. While the vehicle-treated control
tumors grew rapidly, the ALW-treated tumors showed complete inhibition of tumor growth for 7
days, and notably even showed tumor regression for the first 3 days of treatment (Figure 22D).
Furthermore, consistent with mystudies of EphA2 knockdown in vitro, tumors of mice treated
with ALW showed a dramatic decrease in phosphorylation of EphA2 and its downstream targets
p-AKT, p-JAK1 and p-STAT3 (Figure 22E). Overall, these results demonstrated that therapeutic
targeting of EphA2 impaired growth and progression of HCC in vitro and in vivo.
EFNA1 Ligand Activates EphA2 Receptor and AKT and JAK1/STAT3 Signaling in HCC
Given the clinical relevance of high EphA2 ligand expression in HCC. I next test whether
a known EphA2 ligand, EFNA1, can promote the signaling of EphA2 effectors discovered in this
study. I plated Huh7 cells and supplemented in the media with 0.1μg of EFNA1, and found that
EFNA1 can promote EphA2 signaling as early as 2 hours after ligand stimulation (Figure 23).
Furthermore, the activation of AKT, JAK1 and STAT3 signaling, as indicated by the enhanced
phosphorylation, directly correlate to the activation of EphA2 signaling, suggesting that EFNA1
can activated EphA2 and subsequently promote AKT and JAK1/STAT3 signaling in HCC cells.
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Figure 23. Recombinant EFNA1-fc Activates EphA2 Signaling and Its Downstream
Effectors Such as AKT and JAK1/STAT3 in HCC. Cell lysates of Huh7 treated with 0.1
μg/mL of EFNA-fc at indicated times (red arrow) were immunoblotted for Y588 p-EphA2,
EphA2, p-JAK1, p-STAT3, and p-AKT. GAPDH as loading control.
EphA2 Promotion of JAK1/STAT3 Signaling is Not Due to Enhanced IL6 Activity
Because Interleukin-6 (IL-6) is the canonical pathway for the activation of STAT3, I also
assessed whether EphA2 can regulate IL-6 expression. To do this, I compared EphA2
knockdown with scrambled control Huh7 cells, and found that IL6 and IL6 receptor genes (IL6R
and ILST had no significant changes in the mRNA expression levels (Figure 24). This suggests
that EphA2 regulation of JAK1/STAT3 signaling is most likely not due to the promotion of IL6
signaling.

Figure 24. Knockdown of EphA2 Did Not Affect the Expression of IL-6 and IL6
Receptor Related Genes. Normalize RNA expression of IL6, ILR, IL6ST in scramble
(shCtrl) or EphA2 knockdown (shEphA2) Huh7 cell. (n = 3)
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EphA2 and FAK are Signally Independent in HCC
Our lab has previously shown that focal adhesion kinase (FAK) can promote HCC
oncogenesis (Shang et al., 2015; Shang et al., 2019). Furthermore, EphA2 have been shown to
regulate FAK in other tissues (Carter, Nakamoto, Hirai, & Hunter, 2002; Hui Miao, Burnett,
Kinch, Simon, & Wang, 2000). I want to know whether EphA2 can regulate FAK activity in the
context of HCC. To do this, I compared the activity of FAK in EphA2 knockdown Hep3B cells
with the scramble control, and found that knocking down of EphA2 had no effect on the activity
or the expression of FAK (Figure 25A). Conversely, lentiviral overexpression of FAK in
SNU387 cells had not effect on EphA2 signaling or expression (Figure 25B). Overall, this
suggests that the activity of EphA2 and FAK are independent from each other in HCC.
A.

B.

Figure 25. EphA2 Signaling and Expression is Independent from FAK in HCC. A. Cell
lysate of EphA2 knockdown Hep3B cell was immunoblotted for p-FAK, total FAK
expression. GAPDH as loading control. B. Cell lysate of FAK overexpression SNU387 cell
was immunoblotted for p-EphA2, total EphA2 expression. GAPDH as loading control.
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RNA-sequencing Reveal Both Novel and Established Signaling Pathways in EphA2
In addition to STAT3 and AKT, gene set enrichment analysis revealed other possible
interesting EphA2 pathways. These include both oncogenic pathways such as KRAS, β-catenin,
and EGFR and non-oncogenic pathways such as myogenesis, adipogenesis and coagulation
(Figure 26). These will be interesting to explore in the future.
A.

B.

C.

D.

E.
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Figure 26. GSEA Analysis Shows Other Novel and Established Pathways are Highly
Enriched in EphA2 Knockdown HCC Cells Compared to Scramble Control. Gene set
enrichment analysis reveals other oncogenic pathways like KRAS, β-CATENIN and EGFR,
and non-oncogenic pathways including myogenesis, adipogenesis and coagulation are highly
enriched in shEphA2 Huh7 cells. Normalized enrichment score (NES).
Loss of EphA2 inhibits AKT and JAK1/STAT3 activity in MET/CAT induced HCC
I previously showed that MET/CAT promotes EphA2 expression and signaling in the
liver of our murine HCC model. Here I also showed that p-AKT, p-JAK1, and p-STAT3 are all
consequently elevated in MET/CAT expression liver cells as early as 10 days after injection
(Figure 27A) Furthermore, knocking out EphA2 in the context of MET/CAT induced liver cells,
suppressed p-AKT, p-JAK1 and p-STAT3 levels (Figure 27B), suggesting that EphA2 is crucial
for the activation of AKT and JAK1/STAT3 signaling in MET/CAT induced HCC. Finally, the
suppression of EphA2 and downstream effectors were sustained in long-term MET/CAT
induction (45 days after injection, Figure 27C). This suggests that inhibition of EphA2 can
provide long-term therapeutic benefits for MET/CAT induced HCC.
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C.

B.

Figure 27. Loss of EphA2 inhibits AKT and JAK1/STAT3 activity in MET/CAT induced
HCC. A. Western blot analysis of indicated proteins from GFP (PT3-GFP) or MET/CAT
mouse liver 7 weeks after injection. ACTIN as loading control. B. Western blot analysis of
indicated proteins from MET/CAT liver 10 days after injection with empty vector (PX330) or
sgEphA2. GAPDH as loading control. C. Livers of MET/CAT mice injected with PX330 or
sgEphA2 were collected at day 45 and immunohistochemically assessed for EphA2, p-AKT,
p-JAK1 and p-STAT3. Scale bars, 100 μm.
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Phospho-Receptor Tyrosine Kinase Array Uncovers EphA2 as a Novel Target of
Cabozantinib, a Recently Approved Drug Against Advanced HCC
Structurally designed to target c-MET and VEGFR2, cabozantinib effectively inhibited
the growth of several HCC cell lines including HepG2 (data not shown). However, further
protein analysis showed that in majority of the HCC cell lines (except for SNU449) there is little
to no c-MET (Figure 28A and 28B) or VEGFR2 kinase activity (Figure 28B). Using phosphorreceptor tyrosine kinase array comparing 500nM cabozantinib treated HepG2 cells with
untreated DMSO control, I found that EphA2 could potentially be a novel target for
cabozantinib, as EphA2 tyrosine phosphorylation was dramatically suppressed after 4 hours of
treatment with cabozantinib (Figure 28B).
A.

B.

Figure 28. EphA2 as a Novel Target of Cabozantinib. A. Immunoblot of 9 different liver
cancer cell lines showing the protein expression of phosphor-cMET and total- cMET levels.
Action as internal control. B. phosphor-receptor tyrosine kinase array comparing 500nM
cabozantinib treated (bottom) vs untreated DMSO control for 4 hours.
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Figure 29. EphA2 Promotes Tumor Initiation and Progression of HCC by JAK1/STAT3
and AKT Signaling. A summary diagram of the role of EphA2 in promoting
hepatocarcinogenesis. Parts of the diagram are adapted from (Brown, Heinrich, & Greten, 2018;
Siddiqui, Sanna, Ahmad, Sechi, & Mukhtar, 2015)

CHAPTER FIVE
DISCUSSION
HCC remains as one of the most lethal malignancies worldwide because of immense
challenges in prevention, diagnosis, and treatment of the disease (Villanueva, 2019). Despite
decades of advancements in targeted therapy, the currently approved medications for advanced
HCC provide patients with limited clinical benefits (Llovet, Villanueva, Lachenmayer, & Finn,
2015; Villanueva, 2019). A major challenge to developing effective HCC therapeutics is the lack
of understanding of critical drivers of oncogenesis and tumor progression (Llovet et al., 2015).
Here, we established EphA2 as a novel oncotarget that promotes tumor initiation and progression
in HCC (Figure 28). High EphA2 signaling and expression is observed in HCC patient samples
and is associated with worse clinical outcomes. Inhibition of EphA2 in cell-based and in vivo
models of HCC suppressed tumor initiation and growth. Notably, in our GEMM of HCC,
targeted inhibition of EphA2 by CRISPR/Cas9 greatly delayed tumor development and
prolonged the survival of these mice. Mechanistically, I showed that EphA2 promotes tumor
initiation and progression by dual activation of AKT and JAK1/STAT3 signaling. Importantly,
treatment with a small molecule inhibitor of EphA2 (ALW-II-41-27) suppressed HCC
progression in mice, supporting the therapeutic potential of targeting EphA2 in HCC.
The nature of EphA2 signaling is highly diverse and tissue dependent, and many studies
have reported contradictory responses from the same ligand-EphA2 interaction in different cell
types (Pasquale, 2010; Wykosky & Debinski, 2008). The reasons for this are still unclear. One
possible explanation is that spatio-mechanical properties of EphA2 clustering elicit different
83
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downstream signaling based on the chemophysical properties of the inherent cell type (Himanen
et al., 2010; Kania & Klein, 2016; Salaita et al., 2010). Furthermore, tissue-specific responses are
driven by the pre-programmed epigenetic signatures across tissue types (Haigis, Cichowski, &
Elledge, 2019). Thus, differential clustering of EphA2 governed by pre-determined epigenetic
landscape allows for a wide array and even contradictory cellular responses across cancers. This
is highlighted by how EphA2 regulates AKT in different cancers. For example, in glioblastoma,
ligand-induced EphA2 signaling inactivates AKT by dephosphorylation (Miao et al., 2009). In
contrast, the same ligand-induced EphA2 signaling promotes AKT signaling by phosphorylation
in pancreatic cancer (Chang, Jorgensen, Pawson, & Hedley, 2008). In this study, I found that
functional inhibition of EphA2 decreases AKT activity in HCC in vitro and in vivo models,
suggesting that EphA2 activates AKT in HCC. This is further supported by my experiment
showing that EFNA1-fc (a soluble recombinant EphA2 ligand) was able to activate AKT
signaling in HCC cells (Figure 28), demonstrating that EphA2 signaling promotes AKT activity
in the context of HCC. AKT is activated in up to 31.2% of HCC cases, and plays a crucial role in
the malignant transformation of hepatocytes to HCC (Matter, Decaens, Andersen, &
Thorgeirsson, 2014; Villanueva et al., 2008a). I found that EphA2 activation is significantly
associated with high levels of AKT activity in human HCC (Figure 21A-C). Therefore, targeting
EphA2 could provide an effective therapeutic strategy for AKT driven HCC.
STAT3 is a crucial oncogene in many cancers including HCC (He & Karin, 2011; Yu,
Lee, Herrmann, Buettner, & Jove, 2014). Targeting STAT3 could provide numerous benefits
including inhibition of tumor initiation, growth, metastasis and resistance to conventional- and
immuno-therapy (Huynh, Chand, Gough, & Ernst, 2019; Johnson, O'Keefe, & Grandis, 2018; Yu
et al., 2014). However, STAT3 is often deemed to be “undruggable” due to the lack of an
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intrinsic enzymatic site (Wong et al., 2017). Here, I discovered STAT3 as a novel downstream
target of EphA2 in HCC. While a recent study showed that EphA2 recognizes fungal pathogens
and promotes inflammation in association with JAK2/STAT3 signaling (Swidergall, Solis,
Lionakis, & Filler, 2018), to my knowledge, no study has reported that EphA2 can activate
STAT3 in the context of cancer. For the first time, I discovered that EphA2 activates STAT3 in
HCC (Figure 16 and 17), which is further supported by the finding that EFNA1-fc was able to
activate STAT3 in HCC cells (Figure 23). I investigated, mechanistically, how STAT3 is
regulated by EphA2. Although I found that EphA2 promotes the activation of AKT and AKT is
also known to activate STAT3 (Abdelhamed, Ogura, Yokoyama, Saiki, & Hayakawa, 2016;
Yokogami, Wakisaka, Avruch, & Reeves, 2000), further experiments showed that expression of
constitutively-active AKT did not affect p-STAT3 protein levels in EphA2 KD HCC cells
(Figure 16D), suggesting that STAT3 activation by EphA2 in HCC does not depend on AKT.
Another well-established mechanism of STAT3 activation in cancer is through the para/autocrine release of JAK1/STAT3 activating cytokines, particularly the IL-6/GP130 family
(Johnson et al., 2018; Rebouissou et al., 2009; Taga et al., 1989). This is highly relevant in liver
cancer, as high as 90% of HCC case are caused by chronic inflammation and abnormally
elevated cytokine signaling (Llovet et al., 2016). Constitutive activating mutations in gp130 are
frequently observed in hepatocellular adenoma (a rare benign liver tumor defined by elevated
expression of inflammatory cytokines), and interestingly these mutations always go together with
β-catenin-activating mutations, suggesting a collective effect of both pathways in
hepatocarcinogenesis (Rebouissou et al., 2009). I examined our RNA-sequencing data and found
no statistically significant change in transcript level of IL6/GP130 family genes (IL6, IL6R, and
IL6ST) in EphA2 knockdown Huh7 cells compared to scramble control (Figure 24). This
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suggests that the mechanism of EphA2 in promotion of STAT3 activity is mostly likely not due
to para-/autocrine release of IL6.
Thus, I turned my attention to known STAT3 activators. Janus kinase (JAK) is a group of
non-receptor tyrosine kinases that often serve as crucial signal transducers between membrane
receptor signaling (such as cytokine receptors or RTKs) and downstream intracellular signaling
of STAT3 (Darnell, Kerr, & Stark, 1994; Stark, Kerr, Williams, Silverman, & Schreiber, 1998;
Taga et al., 1989). Most importantly, JAKs are highly activated in many types of cancers
including HCC (Calvisi et al., 2006; He et al., 2013; Johnson et al., 2018). While activating
mutations of JAKs are mostly observed in hematological malignancies (Johnson et al., 2018; Yu
et al., 2014), JAK1 mutations are especially prevalent in HCC (Cerami et al., 2012; Gao et al.,
2013) and its activating mutations were identified in up to 9.1% of HCC cases (Kan et al., 2013).
Furthermore, previous studies showed that other ligand-bound RTKs undergo specific
conformational changes that enable the activation of JAK/STAT3 signaling (Andl et al., 2004;
Huynh et al., 2019), and another member of the Ephrin receptor family, EphA4, can directly
interact with JAK2 and activate STAT3 signaling at the neuromuscular junction (Lai et al.,
2004). While JAK2 and JAK3 are expressed at very low levels in HCC, JAK1 expression is
substantial in HCC cells. Therefore, I suspected that JAK1 is the link between EphA2 and
STAT3. In line with this hypothesis, I showed that EphA2 can promote JAK1/STAT3 signaling
in human and mouse HCC and observed a direct interaction between EphA2 and JAK1 in HCC
cells, and knocking down JAK1 abrogated the activation of STAT3 in HCC cells. Importantly,
my result showed intriguing phenomenon: while canonically, JAKs are thought to be exclusively
in the cytoplasm and associated with transmembrane receptor proteins on the cell membrane
(Darnell et al., 1994; Stark et al., 1998), my data suggests that JAK1 and EphA2 interact in the
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perinuclear region (Figure 20C). Although the exact mechanism is unclear, it is possible that
EphA2 exhibits perinuclear endosomal signaling to activate JAK1/STAT3. Many studies have
shown that receptor tyrosine kinases (RTK), upon ligand binding and activation, are internalized
and can continue to recruit and activate signaling pathways within the intracellular vesicles
(Kermorgant & Parker, 2008; Lemmon & Schlessinger, 2010; Miaczynska, 2013; Sigismund et
al., 2008). Furthermore, studies have shown that EphA2 exhibits diverse signaling in endosomes,
especially in the perinuclear region (Boissier, Chen, & Huynh-Do, 2013; Sabet et al., 2015).
Reports also demonstrated that other RTKs such as EGFR requires clathrin mediated endocytosis
to activate AKT and MAPK (Sigismund et al., 2008), and another RTK c-MET has also been
shown to require trafficking to a perinuclear endosome for the activation of STAT3 (Kermorgant
& Parker, 2008). Thus, I hypothesize that EphA2 activation of JAK1/STAT3 might similarly
depends on the perinuclear trafficking of EphA2 and JAK1. Taken together, my results show that
EphA2 activates STAT3 by interacting with JAK1, and provides a tumor-specific approach to
target STAT3 in HCC. Given the important oncogenic roles of both EphA2 and STAT3 in many
cancers, I suspect that the EphA2/JAK1/STAT3 axis is not limited to HCC. For example,
previous studies provide independent evidence that either EphA2 or STAT3 is critical for glioma
tumor progression, and that they contribute to the glioma stem cell phenotype (Binda et al., 2012;
Schaefer, Ren, Fuller, & Schaefer, 2002; Sherry, Reeves, Wu, & Cochran, 2009; Wykosky,
Gibo, Stanton, & Debinski, 2005). The data regarding EphA2 and STAT3 in gliomas suggest
that the two pathways might be connected to each other in glioma tumors. Future studies should
elucidate the connection between EphA2 and STAT3 in other cancers and explore the
therapeutic potential of targeting EphA2, especially in cancers driven by the STAT3 pathway.
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The oncogenic role of AKT and STAT3 is well-established in many cancers including
HCC, which has prompted the development of multiple inhibitors targeting these pathways (He
& Karin, 2011; Johnson et al., 2018; Matter et al., 2014; Mayer & Arteaga, 2016). In the case of
AKT, studies showed that PI3K/AKT/mTOR pathway is upregulated in 40-50% of HCC, and is
associated with less differentiated tumors, worse clinical outcomes, and earlier recurrence after
surgical resection (Baba et al., 2009; Matter et al., 2014; Villanueva et al., 2008b). AKT
signaling promotes cell survival by increasing protein synthesis, lipogenesis, and energy
metabolism, and in transgenic mice, AKT activation by itself was shown to be sufficient for
HCC development (Kenerson et al., 2013; Matter et al., 2014; Zhou, Lui, & Yeo, 2011).
Importantly, inhibition of AKT has been shown to suppress HCC growth in cell based and in
vivo models (Galicia et al., 2010; Grabinski et al., 2012; Matter et al., 2014; Zhou et al., 2011).
Together with the important oncogenic role of STAT3, the high oncogenic synergy and low
spatiotemporal-molecular redundancy between STAT3 and AKT make them attractive
candidates for combination therapy (Choudhari et al., 2007; Li et al., 2019; Vogt & Hart, 2011;
Yu & Jove, 2004). However, therapeutic targeting of STAT3 and/or AKT is challenging due to
(1) a lack of druggable motifs, (2) development of drug resistance and (3) important
physiological functions in normal tissue whose inhibition leads to severe adverse effects for
patients. Here, I propose that targeting EphA2 could provide a novel approach to dual inhibition
of AKT and STAT3, while possibly providing a solution to these problems for the following
reasons: First, EphA2 signaling is highly activated in HCC, as previous studies showed that as
many as 68.9% and 90% of human HCC tissues had significant EphA2 and EFNA1 expressions,
respectively, and these were positively correlated to invasion, angiogenesis, and tumor
progression (Cui et al., 2010; Lee et al., 2009; Yang et al., 2009). In line with these findings, my
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data showed that 33.3% (51/153) of HCC cases had high expression of Y588 p-EphA2 (Figure
4A and 4B). Second, targeting EphA2 simultaneously suppressed AKT and STAT3 in HCC
models. Third, because both AKT and STAT3 are highly implicated in therapeutic resistance (M.
Song, Bode, Dong, & Lee, 2019; Yu et al., 2014), clamping down on both pathways
simultaneously by targeting EphA2 could potentially enhance the efficacy of conventional
therapies and provide robust and long-lasting clinical benefits for HCC patients
EphA2 have been reported to regulate a diverse repertoire of biological function;
therefore, it’s crucial to recognize the possibility that other important downstream targets could
be regulated by EphA2 in the pathogenesis of HCC. In particular, I assessed whether EphA2
could regulate focal adhesion kinase (FAK), as previous studies, including reports from our lab,
have shown that FAK promotes the development of HCC in mouse models and its expression
and activity correlate to aggressive tumor and poor clinical outcomes (Chen et al., 2010; Shang
et al., 2015; Shang et al., 2019). Furthermore, aberrant regulation of FAK by EphA2 was shown
to be responsible for many pathologies including cancer (Brantley-Sieders et al., 2008; Carter,
Nakamoto, Hirai, & Hunter, 2002; Miao, Burnett, Kinch, Simon, & Wang, 2000; Tawadros,
Brown, Hart, & Clarke, 2012). Interestingly, my result suggest that EphA2 does not regulate
FAK in the context of HCC (Figure 25A) as knocking down EphA2 does not affect FAK
signaling or expression, highlighting again the complexity and the high tissue dependency of
EphA2 signaling. Moreover, overexpression of FAK does not affect EphA2 signaling or
expression (Figure 25B), suggesting that EphA2 signaling in HCC is independent from FAK.
Considering the diverse biological functions of EphA2 signaling and the lack of
understanding of its functions in HCC, further investigation of its role in HCC is warranted. In
addition to the two pathways highlighted in this study, GSEA also revealed oncogenic pathways
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such as RAS/MAPK, Wnt/β-Catenin, and EGFR (Figure 26), which were shown to be regulated
by EphA2 signaling in other cancers (De Robertis et al., 2017; Huang et al., 2014; Macrae et al.,
2005). Interestingly, our RNA-analysis showed that the top enriched pathway is myogenesis
(Figure 26). This further confirms the importance of EphA2 signaling in stemness and embryonic
development, especially in the early differentiation of mesenchymal stem cells, as previous
reports showed that bidirectional EphA2 signaling is essential for pre and post-natal myogenesis
(Alonso-Martin et al., 2016; Minami, Koyama, Wakayama, Fukuhara, & Mochizuki, 2011).
Estrogen response genes was also highly enriched (Figure 26). Although the mechanism of
EphA2 regulation on estrogen signaling is not clear, many studies have shown that
overexpression of EphA2 correlate to more aggressive, estrogen-independent, and therapyresistance breast cancer variant (Brantley-Sieders et al., 2008; Gokmen-Polar et al., 2009; Lu,
Miller, Gokmen-Polar, Jeng, & Kinch, 2003; W. Song et al., 2017; Zelinski, Zantek, Stewart,
Irizarry, & Kinch, 2001). In the future, we aim to study how EphA2 regulate other crucial
oncogenic pathways in HCC.
In this project, I have demonstrated the crucial role of EphA2 in promoting tumor
development in our in vivo murine HCC model. Specifically, I showed that EphA2 is essential
for the initiation and progression of c-MET + β-catenin driven HCC, as knocking out EphA2
dramatically reduced liver tumor burden compared to control (Figure 12 and 13). Most
intriguingly, the EphA2 knockout mice that eventually developed tumor exhibited an “escaped”
phenomenon, as micro-dysplastic nodes, histologically resembling to early HCC, was observed
in EphA2 knockout mice as early as 55 days (Figure 14C and 14D). In addition, almost all of
these micro-nodes exhibited reoccurrence of EphA2 expression (Figure14C and 14D),
suggesting that EphA2 is essential for initiation of c-MET and β-catenin driven HCC. The next
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important question to ask is “where does these EphA2 came from?” I showed that my CRISPRCas9 system effectively ablated EphA2 expression 10 days after injection (Figure 12). However,
like in any gene editing system, there is no such thing as 100% efficacy. This is especially true
for the CRISPR-Cas9 system used in this study, as previous studies showed that wild type/nonchemically modified CRISPR-Cas9 system are highly susceptible to ineffective or off-target
modifications (Wu, Kriz, & Sharp, 2014). This inefficiency is due to many factors, including
delivery method, sgRNA design, genetic and epigenetic variability among target cells (Bosch et
al., 2020; Wu, Kriz, et al., 2014). While efficient and safe, the in vivo hydrodynamic gene
delivery method is not the most effective, and depends heavily on the physical property of the
cargo such as size, charge and sterics (Suda & Liu, 2007). Furthermore, the epigenetic variability
with in host liver cells such as chromatin structure and DNA methylation can also prevent the
accessibility and hybridization of sgRNA with the targeted sequence, allowing the host cells to
escape CRISPR deletion (Wu, Scott, et al., 2014).
It is important to indicate some of the important limitations and unanswered questions to
this study. First, in the FACS experiment, I showed that EphA2 expression is directly correlated
with EPCAM expression. However, this is insufficient evidence to suggest that EphA2 can
promote EPCAM protein expression. A better experiment to do in the future is to perform FACS
analysis comparing the protein expression of EPCAM in EphA2 knockdown vs scramble control
HCC cells. Or, show that EphA2 inhibitor, ALW-II-41-27, can suppress EPCAM expression. If
knocking down or inhibiting EphA2 can effectively suppress EPCAM expression, then this will
suggest EphA2 plays a role in promoting EPCAM expression in HCC. Second, I encountered
major difficulties in obtaining viable cells for the in vivo limiting dilution experiment.
Specifically, I was not able to collect sufficient EphA2 high or low expressing Huh7 and Hep3B
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cells, as many cells were not viable after the cell sorting process. Therefore, I was only able to
conduct this experiment with 3 animals in each group, which achieved sub-par statistical power
for this experiment. Nevertheless, my result showed that EphA2 high expressing cells exhibited
greater tumorigenicity.
Second, in the AKT rescue experiment, the shEphA2-2 +EV did not show lower
phosphor-serine 473 (S473) activity compared to the original knockdown data 7 days after
selection. There are couple of possible explanations for this result: 1) EphA2, similar to most
receptor tyrosine kinases (RTK), regulates AKT through PI3K (Manning & Toker, 2017; G.
Song, Ouyang, & Bao, 2005). Literatures showed that phosphorylation at the threonine 308
position (T308) is dependent on PI3K and required for AKT activity while S473 is required for
full activation (Manning & Toker, 2017; G. Song et al., 2005). 2) I found that EphA2 regulation
of S473 is temporally dependent. Between 7 days to 2 weeks after selection shEphA2 showed
suppressed S473 AKT activity, while further than 3 weeks of selection showed gradual recovery
of S473 activity. Perhaps EphA2 has a direct effect on T308 status, and S473, which its
phosphorylation depends on many other kinases, is less dependent on EphA2 activation.
Third, throughout my study, I quantified and measured phospho-Y588 EphA2 protein
level to show that EphA2 forward signaling promotes hepatocarcinogenesis via JAK1/STAT3
and AKT pathways. Although juxtamembrane phosphorylation at Y588 is essential for EphA2
forward signaling activity (Fang, Brantley-Sieders, Hwang, Ham, & Chen, 2008; Kania & Klein,
2016; Wykosky & Debinski, 2008), I cannot rule out the possible contribution of EphA2 reverse
signaling in promoting HCC. In the future, to test whether EphA2 reverse signaling also plays a
role in promoting HCC, we can treat HCC cells with soluble EphA2 recombinant protein and
observed whether free EphA2 can promote tumor development.
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To my knowledge, I showed for the first time that EphA2 can interact with JAK1 in cells.
However, many questions still remain to be answered, such as: 1. Is this interaction ligand
dependent? 2. Does this interaction depends on phosphorylation at Y588 on EphA2? How does
this interaction affect JAK1 activation? These are all important questions that need to be answer
to lucid the EphA2/JAK1/STAT3 pathway in HCC. To address the ligand dependency, we can
compare the EphA2/JAK1 interaction between ligand-treated and non-treated cell using PLA. If
significantly more PLA interaction is observed in the ligand treated cells then it will suggest that
ligand can promote the interaction between EphA2 and JAK1. To test whether phosphorylation
at Y588 on EphA2 is required to interact with JAK1, we can use site-mutagenesis and convert
Y588 to A588, and measure the interaction between EphA2 and JAK1 using PLA comparing the
mutated/phospho-dead or wild type EphA2. Finally, to understand the nature of this interaction,
we can begin by using molecular docking/stimulation software to predict the site of interaction.
While stimulating and studying the structural function of these sites, we can develop hypothesis
on the consequence of this interaction. Simultaneously, we can validate this interaction using Xray crystallography or multi-dimensional NMR. When specific structures are obtained, we can
ultimately use recombinant chemistry to assess the function and consequence of this interaction.
It’s important to clarify the molecular difference between early and late MET/CAT
induced HCC. I choose 10 days after injection to confirm the efficacy of our MET/CAT sleeping
beauty transposon system, because previously our lab have demonstrated that MET and CAT
expression can be observed as early as 7 days after hydrodynamic gene delivery (Shang et al.,
2016; Shang et al., 2015; Shang et al., 2019). Experimentally, analysis of early MET/CAT liver
captures more direct molecular consequence MET/CAT driven hepatocarcinogenesis, as I
showed that as early as 10 days after MET/CAT injection, EphA2 signaling was significantly
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enhance in the liver (Figure 12). This suggests that MET/CAT expression directly promote
EphA2 signaling. However, we do not know whether its c-MET or β-Catenin or both that
promotes EphA2 signaling in liver. Some study suggests that Wnt/β-catenin pathway can
promote EphA2 expression via c-myc in gastric malignances (Huang et al., 2014; Peng et al.,
2018). Nevertheless, it’s important to determine which gene promotes EphA2 signaling be
individually expression c-MET or β-catenin in our liver model.
Currently, a number of EphA2 therapeutics are in clinical trials for cancers in which the
oncogenic function of EphA2 is well-established, such as breast cancer, melanoma, and
glioblastoma (Boyd, Bartlett, & Lackmann, 2013). However, a majority of therapies do not target
EphA2 functions directly, but use EphA2 as bait. For example, MM-310 is a modified EphA2sensing nanoparticle that delivers docetaxel to EphA2 positive tumors. Although dasatinib has
been investigated clinically as an EphA2 inhibitor, it is non-specific and primarily targets SRC
and ABL (Antonio, Ilaria, Nicola, Angelo, & Vito, 2011). In this study, I demonstrated the
therapeutic potential of targeting EphA2 in HCC by showing that a potent and selective EphA2
inhibitor (ALW-II-41-27) was able to significantly suppress tumor growth in cell based and in
vivo models of HCC (Figure 22). Because ALW-II-41-27 belong to a new class of drugs that
targets EphA2 receptors, it’s important to discuss it’s pharmacological and pharmacokinetic
properties and important limitations that ties closely with its potential to be used in clinic. ALWII-41-27 was developed in Dr. Nathanael Gray’s laboratory, and showed high pharmacological
efficacy against EphA2 as it was structurally designed and combinatorically screen for high
potency and specificity for EphA2 kinase (Choi et al., 2009). However, because of the high
homology between tyrosine kinase domain of Ephrin A class receptors, ALW-II-41-27 shows
non-specific kinase interactions at high concentrations with other Ephrin A class receptors,
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especially EphA3, EphA5 and EphA8 (Choi et al., 2009). Another important limitation comes
from its poor pharmacokinetics as ALW-II-41-27 showed short half-life (0.83 hour), low plasma
exposure (333.7 nM/l), and low bioavailability (24.6%) after oral intake in mice (Amato et al.,
2014). The poor oral pharmacokinetics is most likely due to the first pass effect of the liver.
Perhaps, protective chemically modifications and research in drug delivery method can resolve
this limitation. Nevertheless, my findings support clinical investigation to assess the safety and
efficacy of EphA2 inhibitors such as ALW-II-41-27 in the treatment of advanced HCC,
especially in patients showing activation of EphA2. The development of drugs that target critical
HCC oncodrivers could usher in a new era of HCC therapeutics.
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